<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">72082</article-id><article-id pub-id-type="doi">10.7554/eLife.72082</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Inflammasome activation leads to cDC1-independent cross-priming of CD8 T cells by epithelial cell-derived antigen</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-246421"><name><surname>Deets</surname><given-names>Katherine A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1731-1641</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-246712"><name><surname>Nichols Doyle</surname><given-names>Randilea</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="pa1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-188411"><name><surname>Rauch</surname><given-names>Isabella</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-44759"><name><surname>Vance</surname><given-names>Russell E</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6686-3912</contrib-id><email>rvance@berkeley.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><label>1</label><institution>Division of Immunology and Pathogenesis, Department of Molecular and Cell Biology, University of California, Berkeley</institution><addr-line><named-content content-type="city">Berkeley</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Department of Molecular Microbiology and Immunology, Oregon Health and Science University</institution><addr-line><named-content content-type="city">Portland</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Cancer Research Laboratory, University of California, Berkeley</institution><addr-line><named-content content-type="city">Berkeley</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Howard Hughes Medical Institute, University of California, Berkeley</institution><addr-line><named-content content-type="city">Berkeley</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Wang</surname><given-names>Chyung-Ru</given-names></name><role>Reviewing Editor</role><aff><institution>Northwestern University</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Taniguchi</surname><given-names>Tadatsugu</given-names></name><role>Senior Editor</role><aff><institution>Institute of Industrial Science, The University of Tokyo</institution><country>Japan</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>†</label><p>Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, United States</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>23</day><month>12</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e72082</elocation-id><history><date date-type="received" iso-8601-date="2021-07-09"><day>09</day><month>07</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-12-21"><day>21</day><month>12</month><year>2021</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2021-07-08"><day>08</day><month>07</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.07.08.451636"/></event></pub-history><permissions><copyright-statement>© 2021, Deets et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Deets et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-72082-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-72082-figures-v2.pdf"/><abstract><p>The innate immune system detects pathogens and initiates adaptive immune responses. Inflammasomes are central components of the innate immune system, but whether inflammasomes provide sufficient signals to activate adaptive immunity is unclear. In intestinal epithelial cells (IECs), inflammasomes activate a lytic form of cell death called pyroptosis, leading to epithelial cell expulsion and the release of cytokines. Here, we employed a genetic system to show that simultaneous antigen expression and inflammasome activation specifically in IECs is sufficient to activate CD8<sup>+</sup> T cells. By genetic elimination of direct T cell priming by IECs, we found that IEC-derived antigens were cross-presented to CD8<sup>+</sup> T cells. However, cross-presentation of IEC-derived antigen to CD8<sup>+</sup> T cells only partially depended on IEC pyroptosis. In the absence of inflammasome activation, cross-priming of CD8<sup>+</sup> T cells required <italic>Batf3</italic><sup>+</sup> dendritic cells (conventional type one dendritic cells [cDC1]), whereas cross-priming in the presence of inflammasome activation required a <italic>Zbtb46</italic><sup>+</sup> but <italic>Batf3</italic>-independent cDC population. These data suggest the existence of parallel inflammasome-dependent and inflammasome-independent pathways for cross-presentation of IEC-derived antigens.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>inflammasome</kwd><kwd>antigen presentation</kwd><kwd>intestinal epithelial cells</kwd><kwd>adaptive immunity</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AI075039</award-id><principal-award-recipient><name><surname>Vance</surname><given-names>Russell E</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AI063302</award-id><principal-award-recipient><name><surname>Vance</surname><given-names>Russell E</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AI155634</award-id><principal-award-recipient><name><surname>Vance</surname><given-names>Russell E</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000011</institution-id><institution>Howard Hughes Medical Institute</institution></institution-wrap></funding-source><award-id>Investigator Award</award-id><principal-award-recipient><name><surname>Vance</surname><given-names>Russell E</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>5T32GM007232</award-id><principal-award-recipient><name><surname>Deets</surname><given-names>Katherine A</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A mouse model of inducible inflammasome activation in intestinal epithelial cells reveals separate inflammasome-dependent and -independent cross-presentation pathways for epithelial cell-derived antigen.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The innate immune system provides a crucial first line of defense against invading pathogens, and in addition, activates and guides subsequent adaptive immune responses. Although the role of innate immunity in promoting adaptive immunity has long been appreciated (<xref ref-type="bibr" rid="bib36">Janeway, 1989</xref>), most studies have focused on the contributions of Toll-like receptors (TLRs), and significantly less is known about how other innate immune pathways influence the adaptive immune system (<xref ref-type="bibr" rid="bib52">McDaniel et al., 2021</xref>).</p><p>Inflammasomes are a heterogeneous group of cytosolic innate immune sensors, each of which initiates signaling in response to specific stimuli, including pathogen-associated molecules and activities or cellular damage (<xref ref-type="bibr" rid="bib1">Awad et al., 2018</xref>; <xref ref-type="bibr" rid="bib19">Downs et al., 2020</xref>; <xref ref-type="bibr" rid="bib63">Palazon-Riquelme and Lopez-Castejon, 2018</xref>). Regardless of the input signal, a common output of inflammasome activation is the recruitment and activation of caspase proteases (e.g., Caspase-1), which cleave and activate the inflammatory cytokines pro-interleukin (IL)-1β and pro-IL-18 and/or the pore-forming protein gasdermin D. Active gasdermin D oligomerizes in the plasma membrane to form pores that serve as a conduit for the release of active IL-1β and IL-18. Active gasdermin D can also initiate pyroptotic cell death and/or lysis (<xref ref-type="bibr" rid="bib15">de Vasconcelos et al., 2019</xref>; <xref ref-type="bibr" rid="bib17">DiPeso et al., 2017</xref>; <xref ref-type="bibr" rid="bib24">Evavold et al., 2018</xref>; <xref ref-type="bibr" rid="bib29">He et al., 2015</xref>; <xref ref-type="bibr" rid="bib30">Heilig et al., 2018</xref>; <xref ref-type="bibr" rid="bib38">Kayagaki et al., 2015</xref>; <xref ref-type="bibr" rid="bib73">Shi et al., 2015</xref>). In intestinal epithelial cells (IECs), inflammasome activation also results in the expulsion of cells from the epithelial monolayer into the intestinal lumen. Pyroptosis and cell expulsion provide host defense against intracellular pathogens by eliminating their replicative niche (<xref ref-type="bibr" rid="bib26">Fattinger et al., 2021</xref>; <xref ref-type="bibr" rid="bib28">Hausmann et al., 2020</xref>; <xref ref-type="bibr" rid="bib55">Mitchell et al., 2020</xref>; <xref ref-type="bibr" rid="bib67">Rauch et al., 2017</xref>; <xref ref-type="bibr" rid="bib71">Sellin et al., 2014</xref>).</p><p>The role of inflammasome activation during adaptive immunity remains incompletely understood, and inflammasomes appear to have both beneficial and detrimental effects on the adaptive response, depending on the context (<xref ref-type="bibr" rid="bib16">Deets and Vance, 2021</xref>; <xref ref-type="bibr" rid="bib23">Evavold and Kagan, 2018</xref>). In addition, most studies to date use whole-animal knockouts and intravenous infection models, making it difficult to draw conclusions about the effects of inflammasome activation within different cell types. While there remains limited evidence on how inflammasome activation and pyroptosis of either hematopoietic cells or IECs impacts presentation of cell-derived antigens, systemic IL-1β and IL-18 have been implicated in driving type one helper T cell (Th1), Th17, and CD8<sup>+</sup> T cell immunity following bacterial infections (<xref ref-type="bibr" rid="bib40">Kupz et al., 2012</xref>; <xref ref-type="bibr" rid="bib62">O’Donnell et al., 2014</xref>; <xref ref-type="bibr" rid="bib65">Pham et al., 2017</xref>; <xref ref-type="bibr" rid="bib77">Tourlomousis et al., 2020</xref>; <xref ref-type="bibr" rid="bib78">Trunk and Oxenius, 2012</xref>). Likewise, CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses to influenza have been shown to require inflammasome signaling components, presumably in lung macrophages (<xref ref-type="bibr" rid="bib35">Ichinohe et al., 2009</xref>). However, inflammasome activation has also been found to inhibit T cell-mediated immunity (<xref ref-type="bibr" rid="bib69">Sauer et al., 2011</xref>; <xref ref-type="bibr" rid="bib76">Theisen and Sauer, 2017</xref>), including through the pyroptotic destruction of key antigen presenting cells (APCs) (<xref ref-type="bibr" rid="bib51">McDaniel et al., 2020</xref>; <xref ref-type="bibr" rid="bib77">Tourlomousis et al., 2020</xref>). Inflammasomes have also been suggested to influence adaptive responses to tumors (reviewed in <xref ref-type="bibr" rid="bib16">Deets and Vance, 2021</xref>; <xref ref-type="bibr" rid="bib23">Evavold and Kagan, 2018</xref>).</p><p>Most studies to date have evaluated the effects of inflammasome activation on adaptive immunity in the context of infections. Though physiologically relevant, microbial infections are also complex to analyze since they engage multiple innate receptors, including TLRs. It thus remains unknown whether inflammasome activation alone provides sufficient co-stimulatory signals to initiate an adaptive response, and if so, which inflammasome-containing cell populations can drive this response. In addition, the fate of antigens after inflammasome activation remains poorly understood. Conceivably, expulsion of pyroptotic epithelial cells may result in the loss of antigen, thereby hindering adaptive immunity, or alternatively, pyroptosis may promote the release of epithelial or hematopoietic cell antigens to APCs to activate adaptive immunity.</p><p>To investigate how inflammasome activation might influence adaptive immunity, we focused on the NAIP–NLRC4 inflammasomes, which specifically respond to flagellin (via NAIP5/6) or bacterial type III secretion system proteins (via NAIP1/2) (<xref ref-type="bibr" rid="bib39">Kofoed and Vance, 2011</xref>; <xref ref-type="bibr" rid="bib66">Rauch et al., 2016</xref>; <xref ref-type="bibr" rid="bib83">Zhao et al., 2016</xref>; <xref ref-type="bibr" rid="bib82">Zhao et al., 2011</xref>). Although most inflammasomes require the adaptor protein Apoptosis-associated Speck-like protein containing a Caspase activation and recruitment domain (ASC) to recruit and activate pro-Caspase-1, NLRC4 is able to bind and activate pro-Caspase-1 directly—though ASC (encoded by the <italic>Pycard</italic> gene) has been found to enhance the production of IL-1β and IL-18 (<xref ref-type="bibr" rid="bib5">Broz et al., 2010a</xref>; <xref ref-type="bibr" rid="bib6">Broz et al., 2010b</xref>; <xref ref-type="bibr" rid="bib49">Mariathasan et al., 2004</xref>). Cleavage of gasdermin D does not require ASC following NAIP–NLRC4 activation (<xref ref-type="bibr" rid="bib29">He et al., 2015</xref>; <xref ref-type="bibr" rid="bib38">Kayagaki et al., 2015</xref>; <xref ref-type="bibr" rid="bib73">Shi et al., 2015</xref>). NAIPs and NLRC4 are highly expressed in IECs, where they provide defense against enteric bacterial pathogens including <italic>Citrobacter</italic> (<xref ref-type="bibr" rid="bib60">Nordlander et al., 2014</xref>), <italic>Salmonella</italic> (<xref ref-type="bibr" rid="bib26">Fattinger et al., 2021</xref>; <xref ref-type="bibr" rid="bib28">Hausmann et al., 2020</xref>; <xref ref-type="bibr" rid="bib67">Rauch et al., 2017</xref>; <xref ref-type="bibr" rid="bib71">Sellin et al., 2014</xref>), and <italic>Shigella</italic> (<xref ref-type="bibr" rid="bib55">Mitchell et al., 2020</xref>). Inflammasome-driven IEC expulsion appears to be a major mechanism by which NAIP–NLRC4 provides innate defense against enteric pathogens. However, it is not currently known how pyroptosis and IEC expulsion influence the availability of IEC-derived antigens and what impact this has on the adaptive immune response.</p><p>Indeed, even at steady state in the absence of inflammasome activation and pyroptosis, it remains unclear how antigens present in IECs are delivered to APCs to stimulate adaptive immune responses, or whether perhaps IECs can directly activate T cells (<xref ref-type="bibr" rid="bib11">Chulkina et al., 2020</xref>; <xref ref-type="bibr" rid="bib31">Heuberger et al., 2021</xref>; <xref ref-type="bibr" rid="bib45">Liu and Lefrançois, 2004</xref>; <xref ref-type="bibr" rid="bib56">Nakazawa et al., 2004</xref>). Conventional type one dendritic cells (cDC1s) are thought to acquire apoptotic bodies from IECs and shuttle the cell-associated antigens through the MHC II pathway to drive a tolerogenic CD4<sup>+</sup> T cell response under homeostatic conditions (<xref ref-type="bibr" rid="bib12">Cummings et al., 2016</xref>; <xref ref-type="bibr" rid="bib34">Huang et al., 2000</xref>). cDC1s were also recently shown to induce Foxp3<sup>+</sup>CD8<sup>+</sup> T<sub>regs</sub> through the cross-presentation of IEC-derived tissue-specific antigens (<xref ref-type="bibr" rid="bib37">Joeris et al., 2021</xref>). Additionally, in the context of inflammation, a subset of migratory cDC1s have been shown to also take up IEC-derived antigen to activate CD8<sup>+</sup> T cells; however, it remains unclear how these cDC1s acquire IEC-derived antigen.</p><p>Because NAIP–NLRC4 activation can result in IEC pyroptosis prior to the expulsion of IECs from the epithelium (<xref ref-type="bibr" rid="bib67">Rauch et al., 2017</xref>), we hypothesized that cell lysis could release antigen basolaterally, which could then be taken up by cDC1s and cross-presented to CD8<sup>+</sup> T cells. To address the role of inflammasome-induced cell death in antigen presentation and subsequent activation of CD8<sup>+</sup> T cells, we used a genetic mouse model in which an ovalbumin (Ova)-flagellin (Fla) fusion protein is inducibly expressed specifically in IECs (<xref ref-type="bibr" rid="bib58">Nichols et al., 2017b</xref>). The OvaFla fusion protein provides a model antigenic epitope (SIINFEKL) to activate specific CD8<sup>+</sup> (OT-I) T cells (<xref ref-type="bibr" rid="bib33">Hogquist et al., 1994</xref>), concomitant with the activation of the NAIP–NLRC4 inflammasome by a C-terminal fragment of flagellin that does not activate TLR5. This genetic system has the advantage of selectively activating inflammasome responses in the absence of exogenous or pathogen-derived TLR ligands, allowing us to address the sufficiency of inflammasome activation for adaptive responses. Our results suggest the existence of distinct NLRC4-dependent and NLRC4-independent pathways for cross-presentation of IEC-derived antigens in vivo.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Genetic system for NAIP–NLRC4 activation in IECs</title><p>We took advantage of a previously established mouse model (<xref ref-type="bibr" rid="bib58">Nichols et al., 2017b</xref>) that allows for Cre-inducible and cell type-specific NAIP–NLRC4 activation (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). These mice harbor an OvaFla gene fusion that encodes a non-secreted chicken ovalbumin protein—a model antigen—fused to the C-terminal 166 amino acids of flagellin that functions as an agonist of NAIP–NLRC4 but not TLR5 (<xref ref-type="bibr" rid="bib58">Nichols et al., 2017b</xref>). The OvaFla gene is inserted within the constitutively expressed <italic>Rosa26</italic> locus, downstream of a floxed transcriptional stop cassette and upstream of an IRES-GFP cassette. To create a genetic system for inducible NAIP–NLRC4 activation in IECs, we crossed the OvaFla mice to Villin-Cre-ER<sup>T2</sup> mice (<xref ref-type="bibr" rid="bib20">el Marjou et al., 2004</xref>), which harbor a tamoxifen-inducible Cre recombinase driven by the <italic>Villin</italic> promoter. The resulting OvaFla Villin-Cre-ER<sup>T2</sup> (hereafter shortened to ‘OvaFla’) mice respond to tamoxifen administration by expressing Cre, and subsequently the OvaFla protein, specifically in IECs. To study the influence of NAIP–NLRC4 activation, pyroptosis, and cytokine production on CD8<sup>+</sup> T cell activation, we generated <italic>Nlrc4<sup>–/–</sup></italic>, <italic>Gsdmd<sup>–/–</sup></italic>, and <italic>Pycard<sup>–/–</sup></italic> OvaFla lines.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Genetic OvaFla VillinER-Cre<sup>T2</sup> system results in NAIP–NLRC4 activation in intestinal epithelial cells (IECs) of mice upon tamoxifen chow administration.</title><p>(<bold>A</bold>) Schematic of the OvaFla gene cassette in the <italic>Rosa26</italic> locus. The cassette contains full-length mature (non-secreted) ovalbumin fused to the C-terminal 166 amino acids of flagellin, and an IRES-GFP. When OvaFla mice are crossed to mice containing the tamoxifen-inducible Villin-ER-Cre<sup>T2</sup>, tamoxifen administration results in Cre-controlled excision of the stop cassette and expression of the OvaFla fusion protein and GFP within IECs. (<bold>B</bold>) Daily weight (top) and rectal temperature (bottom) measurements of OvaFla mice during a 2-day course of tamoxifen chow (depicted as red bar). (<bold>C</bold>) Quantification of IL-18 ELISA performed on serum from the mice shown in panel B at day 2 post tamoxifen chow start. Each dot represents an individual mouse. (<bold>D</bold>) Daily weight (top) and rectal temperature (bottom) measurements of OvaFla mice following a single day pulse of tamoxifen chow (depicted as red bar). (<bold>E</bold>) Quantification of IL-18 ELISA performed on serum from the mice shown in panel D at day 5 post tamoxifen chow start. (B–E) Data shown as mean ± SD and are from a single representative experiment. Each dot represents an individual mouse. Significance calculated using one-way ANOVA and Tukey’s multiple comparisons test (*p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001). See <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref> for exact p values.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Statistical data and individual data points for <xref ref-type="fig" rid="fig1">Figure 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-72082-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72082-fig1-v2.tif"/></fig><p>Tamoxifen is typically administered in a corn oil emulsion through oral gavage or intraperitoneal injection. In preliminary experiments, we found corn oil contains trace bacterial contaminants that activate TLR signaling (<xref ref-type="bibr" rid="bib57">Nichols, 2017a</xref>). Thus, to avoid confounding effects of TLR activation, and to isolate the specific effects of inflammasome activation, we administered tamoxifen orally through a commercially available tamoxifen-containing chow. OvaFla mice were fed ab libitum, and their weight and temperature were tracked daily as previously described indicators of NAIP–NLRC4 activation (<xref ref-type="bibr" rid="bib80">von Moltke et al., 2012</xref>). After a single day on the tamoxifen diet, wild-type (WT) OvaFla and <italic>Gsdmd<sup>–/–</sup></italic> OvaFla mice lost a significant amount of weight, and by day 2 of the tamoxifen diet, these mice exceeded the humane weight loss endpoint on our animal protocol and were euthanized (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, top). In contrast, the <italic>Nlrc4<sup>–/–</sup></italic> OvaFla mice, as well as the OvaFla-only and Cre-only littermate control mice, maintained a consistent body weight and appeared healthy over the 2-day time course. Although not statistically significant, the WT OvaFla and <italic>Gsdmd<sup>–/–</sup></italic> OvaFla mice also exhibited decreases in core body temperature by day 2 relative to the <italic>Nlrc4<sup>–/–</sup></italic> OvaFla mice (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, bottom), consistent with previous analyses using recombinant flagellin protein (FlaTox) to induce acute NAIP–NLRC4 activation (<xref ref-type="bibr" rid="bib67">Rauch et al., 2017</xref>; <xref ref-type="bibr" rid="bib80">von Moltke et al., 2012</xref>).</p><p>Serum was collected from OvaFla mice at day 2 of the tamoxifen diet and assayed for IL-18, which is released from IECs following NAIP–NLRC4 activation (<xref ref-type="bibr" rid="bib67">Rauch et al., 2017</xref>). The serum of WT OvaFla mice contained approximately 60 times more IL-18 than the serum of <italic>Gsdmd<sup>–/–</sup></italic> OvaFla mice, demonstrating that gasdermin D is required for IL-18 release from IECs following NAIP–NLRC4 activation (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). IL-18 was not detected in the <italic>Nlrc4<sup>–/–</sup></italic> mice or in the OvaFla-only or Cre-only littermate controls. Taken together, these data show that the OvaFla system results in robust NAIP–NLRC4 activation in IECs following tamoxifen administration.</p><p>To limit confounding effects of morbidity in the NAIP–NLRC4 sufficient strains, we shortened the administration of tamoxifen chow to a single day pulse. We again monitored weight and rectal temperature each day. We found that while the WT, <italic>Pycard<sup>–/–</sup></italic>, and <italic>Gsdmd</italic><sup>–/–</sup> OvaFla mice initially lost weight, weight loss was reversed within 2 days of being fed normal chow (<xref ref-type="fig" rid="fig1">Figure 1D</xref>, top). No significant difference in core body temperature was found between strains over the 5-day experiment (<xref ref-type="fig" rid="fig1">Figure 1D</xref>, bottom).</p><p>Serum was collected at day 5 post start of the tamoxifen chow diet and again assayed for IL-18 through ELISA. Similar to the 2-day tamoxifen pulse, a single day of tamoxifen chow resulted in significant IL-18 production in the WT OvaFla mice but minimal to no detectable IL-18 in the other OvaFla strains (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). The WT mice exhibited heterogeneity in the IL-18 response with the single day chow pulse, which may be related to some mice being averse to consuming the tamoxifen chow (<xref ref-type="bibr" rid="bib9">Chiang et al., 2010</xref>) or heterogeneity in the kinetics of the response.</p><p>We also performed immunofluorescence imaging of the small intestines of mice from each of the OvaFla lines after a single day pulse of tamoxifen chow. The presence of an IRES-GFP downstream of the OvaFla gene allows us to track the expression of the transgene. While approximately 30% of the IECs were GFP<sup>+</sup> in <italic>Nlrc4<sup>–/–</sup></italic> OvaFla mice, only about 2% of the IECs were GFP<sup>+</sup> in the WT, <italic>Pycard<sup>–/–</sup></italic>, or <italic>Gsdmd<sup>–/–</sup></italic> OvaFla mice at that time point (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>). Additionally, of those GFP<sup>+</sup> cells, IECs in the <italic>Nlrc4<sup>–/–</sup></italic> OvaFla mice contained significantly more GFP signal when compared with the other OvaFla lines, whereas transgene expression was indistinguishable among WT, <italic>Pycard</italic><sup>–/–</sup>, and <italic>Gsdmd</italic><sup>–/–</sup> mice (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Low transgene expression in genotypes other than <italic>Nlrc4</italic><sup>–/–</sup> was anticipated because previous work (<xref ref-type="bibr" rid="bib67">Rauch et al., 2017</xref>; <xref ref-type="bibr" rid="bib71">Sellin et al., 2014</xref>) found that IECs are rapidly expelled from the epithelium upon NAIP–NLRC4 activation. Given that we observe robust IL-18 levels in the serum of WT mice (<xref ref-type="fig" rid="fig1">Figure 1C and E</xref>), we believe the transgene is expressed in WT (and <italic>Pycard</italic><sup>–/–</sup> and <italic>Gsdmd</italic><sup>–/–</sup>) mice, but NLRC4<sup>+</sup> cells that express high levels of the transgene are expelled, limiting our ability to detect them. Although pyroptosis of IECs requires gasdermin D, NAIP–NLRC4-induced IEC expulsion was previously found to be independent of gasdermin D, likely due to the existence of an NLRC4-Caspase-8-dependent apoptosis pathway that also leads to IEC expulsion (<xref ref-type="bibr" rid="bib48">Man et al., 2013</xref>; <xref ref-type="bibr" rid="bib67">Rauch et al., 2017</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>GFP<sup>+</sup> cells accumulate in <italic>Nlrc4<sup>–/–</sup></italic> OvaFla mice following tamoxifen administration.</title><p>(<bold>A</bold>) Representative immunofluorescence images of the small intestines of indicated OvaFla mice on day 2 following a single day pulse of tamoxifen chow. (<bold>B</bold>) Quantification of DAPI<sup>+</sup> IECs that are also GFP<sup>+</sup> for each OvaFla line. Approximately 100 cells from least 15 separate villi across four to five images were counted per mouse. (<bold>C</bold>) Quantification of mean GFP pixel intensity for GFP<sup>+</sup> intestinal epithelial cells (IECs) in each OvaFla line. Data represent an averaged value from 12 to 20 cells per image across four to five images per mouse. (B–C) Data are pooled from two biological replicates, and each dot represents an individual mouse. Data shown as mean ± SD. Significance calculated using one-way ANOVA and Tukey’s multiple comparisons test (*p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001). Only p values between wild-type (WT) and other experimental groups are shown. See <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref> for exact p values.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Statistical data for <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-72082-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72082-fig2-v2.tif"/></fig><p>Taken together, these data show that OvaFla production under control of the tamoxifen-inducible Villin-Cre-ER<sup>T2</sup> system results in robust NAIP–NLRC4 activation in the IECs of mice. A single day pulse of tamoxifen chow leads to significant IL-18 production without gross morbidity or mortality in the NAIP–NLRC4 sufficient strains. Additionally, OvaFla likely accumulates in the IECs of the <italic>Nlrc4<sup>–/–</sup></italic> OvaFla mice, as these cells do not undergo NAIP–NLRC4-driven cell expulsion.</p></sec><sec id="s2-2"><title>CD8<sup>+</sup> T cell activation by epithelial antigens</title><p>To understand how NAIP–NLRC4 activation influences IEC-derived antigen release and presentation, we followed the response of Ova-specific TCR transgenic OT-I CD8<sup>+</sup> T cells following OvaFla induction in each of our mouse lines. Congenically marked (CD45.1<sup>+</sup> or CD45.1<sup>+</sup> CD45.2<sup>+</sup>) OT-I T cells were harvested from the spleens and mesenteric lymph nodes of OT-I <italic>Rag2</italic><sup>–/–</sup> mice, labeled with CellTrace Violet proliferation dye, and intravenously transferred into the OvaFla mice (2 × 10<sup>4</sup> cells per mouse) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Immediately following adoptive transfer, the mice were placed on tamoxifen chow for a single day. At day 5 post adoptive transfer, the mice were euthanized, and their mesenteric lymph nodes, which drain immune cells from the intestines (<xref ref-type="bibr" rid="bib22">Esterházy et al., 2019</xref>), and spleens were analyzed for OT-I T cell proliferation and activation.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>OvaFla expression in intestinal epithelial cells (IECs) results in OT-I proliferation and activation that is independent of ASC and NLRC4 but partially dependent on gasdermin D.</title><p>(<bold>A</bold>) Overview of experimental setup for analyzing OT-I responses to OvaFla production in IECs. (<bold>B</bold>) Quantification of OT-Is as a percent of total CD8<sup>+</sup> T cells per spleen (left) and mesenteric lymph node (right). (<bold>C</bold>) Total number of OT-Is per spleen (left) and mesenteric lymph node (right). (<bold>D</bold>) Total number of CD62L<sup>–</sup>CD44<sup>+</sup> OT-Is per spleen (left) and mesenteric lymph node (right). Samples with fewer than 20 OT-Is were excluded from CD62L, CD44 calculations. Tissues were harvested and analyzed at day 5 post tamoxifen chow start. Data are pooled from three biological replicates, and each dot represents an individual mouse. Data shown as mean ± SD. Significance calculated using one-way ANOVA and Tukey’s multiple comparisons test (*p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001). Only p values between wild-type (WT) and other experimental groups are shown. See <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref> for exact p values.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Statistical data for <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-72082-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72082-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>OvaFla expression in intestinal epithelial cells (IECs) results in OT-I proliferation and activation that is independent of ASC and NLRC4 but partially dependent on gasdermin D.</title><p>(<bold>A</bold>) Flow cytometry gating strategy for identifying OT-I T cells. (<bold>B</bold>) Representative histograms of CellTrace Violet dilution for each of the OvaFla mouse lines. (<bold>C</bold>) Representative dot plots of each OvaFla mouse line showing the gating strategy for identifying CD62L<sup>–</sup>CD44<sup>+</sup> OT-Is. (<bold>D</bold>) Percent of OT-Is that are CD62L<sup>–</sup>CD44<sup>+</sup> per spleen (left) and mesenteric lymph node (right). (<bold>E</bold>) Percent of OT-Is from the mesenteric lymph node that are IFNγ<sup>+</sup>TNFα<sup>+</sup> following a 5 hr ex vivo stimulation with phorbol myristate acetate (PMA) (1 μg/mL) and ionomycin (1 μg/mL). (D–E) Data are from three independent experiments, and each dot represents an individual mouse. Tissues were harvested and analyzed at day 5 post tamoxifen chow start. Samples with fewer than 20 OT-Is were excluded from CD62L, CD44, and cytokine calculations. Data shown as mean ± SD. Significance calculated using one-way ANOVA and Tukey’s multiple comparisons test (*p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001). Only p values between wild-type (WT) and other experimental groups are shown. See <xref ref-type="supplementary-material" rid="fig3s1sdata1">Figure 3—figure supplement 1—source data 1</xref> for exact p values.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Statistical data for <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-72082-fig3-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72082-fig3-figsupp1-v2.tif"/></fig></fig-group><p>A dividing OT-I population was identified by flow cytometry in each Cre<sup>+</sup> OvaFla line (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A and B</xref>), indicating that antigens expressed in IECs can be processed and presented to activate CD8<sup>+</sup> T cells in vivo. Surprisingly, however, there was minimal difference in the relative percent (<xref ref-type="fig" rid="fig3">Figure 3B</xref>), absolute number (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), or activation status (defined as CD62L<sup>–</sup>CD44<sup>+</sup>) (<xref ref-type="fig" rid="fig3">Figure 3D</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C,D</xref>) of OT-I T cells between the WT and <italic>Nlrc4<sup>–/–</sup></italic> OvaFla mice in either the spleen or mesenteric lymph node. In fact, relative to the WT OvaFla mice, a higher percent of the OT-I T cells in the <italic>Nlrc4<sup>–/–</sup></italic> OvaFla mice produced IFNγ and TNFα following ex vivo stimulation with PMA and ionomycin (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>). These data indicate OT-I T cells respond to IEC-expressed Ova in a manner that is independent of NAIP–NLRC4 activation. However, the specific lack of IEC expulsion and the resulting higher accumulation of antigen in IECs in <italic>Nlrc4</italic><sup>–/–</sup> mice (<xref ref-type="fig" rid="fig2">Figure 2</xref>) means that the WT and <italic>Nlrc4</italic><sup>–/–</sup> mice are not truly comparable.</p><p>In contrast to <italic>Nlrc4</italic><sup>–/–</sup> IECs, both <italic>Pycard</italic><sup>–/–</sup> and <italic>Gsdmd</italic><sup>–/–</sup> IECs are expelled after inflammasome activation and thus exhibit indistinguishably low OvaFla-IRES-GFP transgene expression in IECs as compared to WT mice (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Both strains are also defective for IL-18 release (<xref ref-type="fig" rid="fig1">Figure 1C and E</xref>). The major difference between the two strains is that <italic>Pycard</italic><sup>–/–</sup> cells can still undergo <italic>Gsdmd</italic>-dependent pyroptosis, whereas <italic>Gsdmd</italic><sup>–/–</sup> cells do not undergo lytic pyroptosis but are nevertheless expelled from the epithelium as intact apoptotic cells, likely via a Caspase-1 and/or -8 pathway (<xref ref-type="bibr" rid="bib48">Man et al., 2013</xref>; <xref ref-type="bibr" rid="bib67">Rauch et al., 2017</xref>). There was little difference in OT-I numbers (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, right, <xref ref-type="fig" rid="fig3">Figure 3C</xref>, right) or activation (<xref ref-type="fig" rid="fig3">Figure 3D</xref>, right, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C,D</xref>, right), as well as no difference in OT-I IFNγ and TNFα production (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>), in the mesenteric lymph nodes of the WT versus <italic>Pycard</italic><sup>–/–</sup> OvaFla mice. However, there were significantly more activated OT-Is in the spleens of the <italic>Pycard</italic><sup>–/–</sup> OvaFla mice (<xref ref-type="fig" rid="fig3">Figure 3C</xref>, right, <xref ref-type="fig" rid="fig3">Figure 3D</xref>, right). These data suggest there may be some suppressive role for ASC in NAIP–NLRC4-dependent activation of CD8<sup>+</sup> T cells in circulation, though future characterization of these findings is needed. In contrast to the <italic>Pycard<sup>–/–</sup></italic> OvaFla mice, the <italic>Gsdmd<sup>–/–</sup></italic> OvaFla mice had a significantly lower number of activated cells relative to the WT OvaFla mice, but this difference was only found in the mesenteric lymph nodes (<xref ref-type="fig" rid="fig3">Figure 3C and D</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>). Taken together, these results suggest that inflammasome activation in IECs is not essential for OT-I CD8<sup>+</sup> T cell activation, yet gasdermin D-mediated pyroptosis of IECs may play a partial role (see Discussion).</p><p>We also observed that a small percentage of OT-Is in the OvaFla only (Cre-minus) mice appear to be activated (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D, E</xref>). Since these mice are lacking Cre recombinase, we suspect there may be a very low level of Cre-independent expression of the OvaFla transgene. This chronic OvaFla expression is likely to result in exhaustion and/or deletion of any endogenous Ova-specific effector T cells (<xref ref-type="bibr" rid="bib41">Kurachi, 2019</xref>). Indeed, we were unable to identify any SIINFEKL-specific endogenous CD8<sup>+</sup> T cells via tetramer staining or ELISpot assays. Furthermore, tamoxifen-induced estrogen receptor signaling in the Villin-Cre-ER<sup>T2</sup> mice is known to occur in crypt stem cells, which leads to tamoxifen-independent Cre expression in the IEC progeny (<xref ref-type="bibr" rid="bib20">el Marjou et al., 2004</xref>). Tamoxifen-independent Cre expression in the OvaFla mice could cause OvaFla to become a chronic stimulus, again likely leading to CD8<sup>+</sup> T cell exhaustion. Because of these potentially complicating factors, we believe our OvaFla system is best suited to follow the immediate fate of IEC-derived antigen using naïve transferred OT-I transgenic T cells.</p></sec><sec id="s2-3"><title>Cross-presentation of IEC antigens</title><p>IECs express MHC class I on their surface and are capable of directly presenting antigen to CD8<sup>+</sup> T cells (<xref ref-type="bibr" rid="bib10">Christ and Blumberg, 1997</xref>; <xref ref-type="bibr" rid="bib56">Nakazawa et al., 2004</xref>). It is therefore possible that the OT-I activation seen in the OvaFla mice is a result of direct presentation of Ova peptide by the IECs expressing OvaFla. However, it is also possible that the OT-I T cells are being cross-primed by cDC1s that engulf and ‘cross-present’ the IEC-derived Ova (<xref ref-type="bibr" rid="bib8">Cerovic et al., 2015</xref>; <xref ref-type="bibr" rid="bib45">Liu and Lefrançois, 2004</xref>). The fate of IEC-derived antigens and the role of antigen presentation pathways leading to CD8<sup>+</sup> T cell activation has not previously been addressed with a completely in vivo system that can genetically distinguish cross from direct presentation of IEC antigens.</p><p>To determine whether the OT-Is are being activated through cross-presentation or direct presentation of Ova peptide, we took advantage of the H-2K<sup>bm1</sup> mouse model that contains a seven base pair mutation in the gene encoding K<sup>b</sup> (<xref ref-type="bibr" rid="bib70">Schulze et al., 1983</xref>). The bm1 mutation renders K<sup>b</sup> unable to bind the Ova-derived OT-I agonist peptide, SIINFEKL (<xref ref-type="bibr" rid="bib59">Nikolić-Zugić and Bevan, 1990</xref>). We bred H-2K<sup>bm1</sup> mice to each of our OvaFla lines to establish mice that make OvaFla in their IECs but are incapable of directly presenting the SIINFEKL peptide (H-2K<sup>bm1+</sup> OvaFla mice, referred to here as bm1<sup>+</sup> OvaFla mice). We then generated bone marrow chimeras using bm1<sup>+</sup> OvaFla mice as lethally irradiated recipients that were reconstituted with WT H-2K<sup>b</sup> bone marrow from B6 CD45.1 donors (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, left). In these chimeras, the IECs produce OvaFla following tamoxifen administration, but the IECs themselves are unable to present SIINFEKL to OT-I T cells. The donor-derived hematopoietic cells, including cross-presenting cDC1s, do not contain the OvaFla gene cassette but are able to cross-present the SIINFEKL peptide if they acquire it from IECs (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, right). Therefore, in the bm1<sup>+</sup> OvaFla chimeras, OT-I proliferation and activation will only be observed if the SIINFEKL peptide is cross-presented.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>OvaFla expression in intestinal epithelial cells (IECs) results in OT-I cross-priming that is independent of NLRC4 but partially dependent on gasdermin D.</title><p>(<bold>A</bold>) Schematic depicting the production and analysis workflow of chimeric bm1<sup>+</sup>OvaFla mice (left). At the right, an illustration of either wild-type (WT) OvaFla mice (left of the dashed line) or <italic>Nlrc4</italic><sup>–/–</sup> OvaFla mice (right of the dashed line) following lethal irradiation and reconstitution with bone marrow from B6.SJL mice. (<bold>B</bold>) Quantification of OT-Is as a percent of total CD8<sup>+</sup> T cells (left), the total number of OT-Is (middle), and the total number of CD62L<sup>–</sup>CD44<sup>+</sup> OT-Is (right) in the spleen. (<bold>C</bold>) Quantification of OT-Is as a percent of total CD8<sup>+</sup> T cells (left), the total number of OT-Is (middle), and the total number of CD62L<sup>–</sup>CD44<sup>+</sup> OT-Is (right) in the mesenteric lymph nodes. Tissues were harvested and analyzed at day 5 post tamoxifen chow start. (B–C) Data are pooled from three biological replicates, and each dot represents an individual mouse. Data shown as mean ± SD. Significance calculated using one-way ANOVA and Tukey’s multiple comparisons test (*p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001). Only p values between WT and other experimental groups are shown. See <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref> for exact p values.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Statistical data for <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-72082-fig4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72082-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>OvaFla expression in intestinal epithelial cells (IECs) of bm1<sup>+</sup>OvaFla mice results in NAIP–NLRC4 expression and OT-I cross-priming that is independent of NLRC4 but partially dependent on gasdermin D.</title><p>(<bold>A</bold>) Quantification of IL-18 ELISA performed on serum from the mice shown in <xref ref-type="fig" rid="fig4">Figure 4</xref> at day 5 post tamoxifen chow start. (<bold>B</bold>) Representative histograms of CellTrace Violet dilution for the indicated OvaFla mouse lines. (<bold>C</bold>) Percent of OT-Is that are CD62L<sup>–</sup>CD44<sup>+</sup> in the spleen (left) and mesenteric lymph nodes (right) of the mice shown in <xref ref-type="fig" rid="fig4">Figure 4</xref>. (<bold>D</bold>) Percent of OT-Is from the mesenteric lymph nodes of the mice in <xref ref-type="fig" rid="fig4">Figure 4</xref> that are IFNγ<sup>+</sup>TNFα<sup>+</sup> following a 5 hr ex vivo stimulation with phorbol myristate acetate (PMA) (1 μg/mL) and ionomycin (1 μg/mL). Tissues were harvested and analyzed at day 5 post tamoxifen chow start. Samples with fewer than 20 OT-Is were excluded from CD62L, CD44, and cytokine calculations. (A) Data are pooled from two biological replicates. (C) Data are pooled from three biological replicates. Each dot represents an individual mouse. Data shown as mean ± SD. Significance calculated using one-way ANOVA and Tukey’s multiple comparisons test (*p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001). Only p values between wild-type (WT) and other experimental groups are shown. See <xref ref-type="supplementary-material" rid="fig4s1sdata1">Figure 4—figure supplement 1—source data 1</xref> for exact p values.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Statistical data for <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-72082-fig4-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72082-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>K<sup>b</sup> donor bone marrow is required for OT-I proliferation and activation in bm1<sup>+</sup> OvaFla bone marrow chimeras.</title><p>(<bold>A</bold>) Schematic depicting the production and analysis workflow of chimeric bm1<sup>+</sup>OvaFla mice that were given either B6 H-2K<sup>b</sup> or H-2K<sup>bm1</sup> bone marrow. (<bold>B</bold>) Representative flow plots demonstrating the absence of OT-Is in the mice given H-2K<sup>bm1</sup> bone marrow, as depicted in A. (<bold>C</bold>) Quantification of the total number of OT-Is (top) and the OT-Is as a percent of total CD8<sup>+</sup> T cells (bottom) in the spleen (left) and mesenteric lymph nodes (right) of bm1<sup>+</sup> wild-type (WT) and bm1<sup>+</sup> <italic>Nlrc4<sup>–</sup></italic> OvaFla mice as depicted in A. Data are from a single experiment, and each dot represents an individual mouse. Data shown in C as mean ± SD.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72082-fig4-figsupp2-v2.tif"/></fig></fig-group><p>Eight to ten weeks after lethal irradiation and reconstitution, bm1<sup>+</sup> OvaFla mice received 2 × 10<sup>4</sup> CD45.1<sup>+</sup> CD45.2<sup>+</sup> CellTrace Violet labeled OT-I T cells intravenously and were given a 1-day pulse of tamoxifen chow (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, left). The mice were euthanized at day 5 post OT-I transfer, and their spleens and mesenteric lymph nodes were analyzed for OT-I proliferation and activation. Serum was also collected for IL-18 ELISA to confirm NAIP–NLRC4-dependent IL-18 release following OvaFla induction (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>).</p><p>As with the non-chimera experiments, an obvious dividing and activated OT-I population was observed by flow cytometry in each of the OvaFla mouse lines (<xref ref-type="fig" rid="fig4">Figure 4B and C</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B, C</xref>). This population was absent in mice given H-2K<sup>bm1</sup> bone marrow (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>), confirming the requirement for APCs to express K<sup>b</sup> to activate OT-I T cells. These data provide formal genetic evidence that IEC-derived antigens can be cross-presented to activate CD8<sup>+</sup> T cells in vivo.</p><p>In the spleen, the bm1<sup>+</sup> WT and bm1<sup>+</sup> <italic>Nlrc4<sup>–/–</sup></italic> OvaFla mice harbored significantly more OT-I T cells than the bm1<sup>+</sup> <italic>Gsdmd<sup>–/–</sup></italic> OvaFla mice, or the bm1<sup>+</sup> OvaFla-only and bm1<sup>+</sup> Cre-only littermate controls, by both percent (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, left) and total number (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, middle). There were also significantly more activated (CD62L<sup>–</sup>CD44<sup>+</sup>) OT-I T cells in the spleens of bm1<sup>+</sup> WT mice as compared to bm1<sup>+</sup> <italic>Gsdmd</italic><sup>–/–</sup> mice (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, right). In the mesenteric lymph nodes, no significant differences were found across any of the OvaFla mouse lines (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C-D</xref>). The reason for the weak responses in the mesenteric lymph nodes is unclear, but others have previously noted negative impacts in irradiation chimeras on the expansion of adoptively transferred OT-I T cells (<xref ref-type="bibr" rid="bib43">Kurts et al., 1997</xref>).</p><p>Taken together, these data provide genetic evidence that OT-I T cells are cross-primed from IEC-derived antigen following OvaFla induction. This cross-priming does not strictly require NAIP–NLRC4 activation, but gasdermin D-induced pyroptosis can promote CD8<sup>+</sup> T cell responses, at least for splenic OT-I T cells.</p></sec><sec id="s2-4"><title>NAIP–NLRC4 activation drives <italic>Batf3<sup>+</sup></italic> cDC1-independent cross-presentation</title><p>Previous work shows that ex vivo cDC1s can cross-prime CD8<sup>+</sup> T cells with IEC-derived antigen (<xref ref-type="bibr" rid="bib8">Cerovic et al., 2015</xref>). To investigate the role of cDC1s in vivo, we first compared the relative number (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref> left) and maturation state (MHC II<sup>high</sup> CD86<sup>+</sup>) (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref> right) of cDC1s in the mesenteric lymph nodes and spleen across the WT, <italic>Pycard<sup>–/–</sup></italic>, <italic>Gsdmd<sup>–/–</sup></italic>, and <italic>Nlrc4<sup>–/–</sup></italic> OvaFla mice after 2 days of tamoxifen chow. Although there was a modest reduction in the relative number of cDC1s in the spleens of <italic>Pycard</italic><sup>–/–</sup> OvaFla mice relative to the WT OvaFla mice, there was otherwise no clear difference in the presence or maturation state of cDC1s across the various OvaFla lines. These data suggest that NAIP–NLRC4 activation in IECs does not have a broad impact on cDC1s.</p><p>However, it is possible that a relatively small number of cDC1s are receiving antigen and maturation signals in our OvaFla model, so we assessed whether cDC1s are required for cross-priming OT-Is by genetically eliminating cDC1s. To do so, we used mice deficient for <italic>Batf3</italic>, a gene encoding a transcription factor required for development of XCR1<sup>+</sup> cross-presenting cDC1s (<xref ref-type="bibr" rid="bib32">Hildner et al., 2008</xref>; <xref ref-type="bibr" rid="bib47">Lukowski et al., 2021</xref>). We took advantage of our H-2K<sup>bm1</sup> bone marrow chimera system and compared bm1<sup>+</sup> OvaFla recipients that received either B6 CD45.1 bone marrow or bone marrow from <italic>Batf3<sup>–/–</sup></italic> mice.</p><p>As with the above experiments, bone marrow chimeras were made by lethally irradiating bm1<sup>+</sup> OvaFla mice and transferring donor bone marrow from either B6 CD45.1 or <italic>Batf3<sup>–/–</sup></italic> donors. Eight to ten weeks post irradiation, 2 × 10<sup>4</sup> CD45.1<sup>+</sup> CD45.2<sup>+</sup> CellTrace Violet labeled OT-I T cells were adoptively transferred intravenously, and the mice were given a 1-day pulse of tamoxifen chow (as in <xref ref-type="fig" rid="fig4">Figure 4A</xref>, left). The mice were sacrificed 5 days later, and their spleens and mesenteric lymph nodes were analyzed for OT-I proliferation and activation. We confirmed an absence of cDC1 cells in the OvaFla mice that received <italic>Batf3<sup>–/–</sup></italic> donor bone marrow (<xref ref-type="fig" rid="fig5">Figure 5A</xref>, <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Cross-priming of OT-Is is independent of <italic>Batf3<sup>+</sup></italic> cDC1s following NAIP–NLRC4 activation in intestinal epithelial cells (IECs).</title><p>(<bold>A</bold>) Percent of CD45<sup>+</sup> cells that are conventional type one dendritic cells (cDC1s) in bm1 chimera mice that received either <italic>Batf3<sup>+</sup></italic> or <italic>Batf3<sup>–</sup></italic> donor bone marrow. (<bold>B</bold>) Quantification of OT-Is as a percent of total CD8<sup>+</sup> T cells (top), the total number of OT-Is (middle), and the total number of CD62L<sup>–</sup>CD44<sup>+</sup> OT-Is (bottom) in the spleen. (<bold>C</bold>) Quantification of OT-Is as a percent of total CD8<sup>+</sup> T cells (top), the total number of OT-Is (middle), and the total number of CD62L<sup>–</sup>CD44<sup>+</sup> OT-Is (bottom) in the mesenteric lymph nodes. (<bold>D</bold>) Quantification of OT-Is that have out-diluted the CellTrace Violet dye in the spleen (top) and mesenteric lymph nodes (bottom). (<bold>E</bold>) Percent of CD62L<sup>–</sup>CD44<sup>+</sup> OT-Is in the mesenteric lymph node that are CCR9<sup>+</sup>. Tissues were harvested and analyzed at day 5 post tamoxifen chow start. Samples with fewer than 20 OT-Is were excluded from CD62L, CD44, and CCR9 calculations. (A) Data are from a single experiment. (B–D) Data are pooled from three biological replicates. (E) Data are pooled from two biological replicates. Each dot represents an individual mouse. Data shown as mean ± SD. Significance calculated using one-way ANOVA and Šídák’s multiple comparisons test (*p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001). See <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref> for exact p values.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Statistical data for <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-72082-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72082-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>NAIP–NLRC4 activation in intestinal epithelial cells (IECs) does not lead to an increase in relative numbers of cDCs or an increase in their maturation state in the mesenteric lymph nodes or spleen.</title><p>(<bold>A</bold>) Flow cytometry gating strategy for identifying conventional type one dendritic cells (cDC1s) and cDC2s. (<bold>B</bold>) Relative numbers (left) and percent of MHC II<sup>high</sup> CD86<sup>+</sup> (right) cDC1s in the mesenteric lymph nodes and spleen 3 days post the start of tamoxifen chow. (<bold>C</bold>) Relative numbers (left) and percent of MHC II<sup>high</sup> CD86<sup>+</sup> (right) cDC2s in the mesenteric lymph nodes and spleen 3 days post the start of tamoxifen chow. See <xref ref-type="supplementary-material" rid="fig5s1sdata1">Figure 5—figure supplement 1—source data 1</xref> for exact p values.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Statistical data for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-72082-fig5-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72082-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Gating demonstration for <xref ref-type="fig" rid="fig5">Figure 5A</xref>.</title><p>Representative dot plots from one bm1<sup>+</sup> wild-type (WT) OvaFla mouse that received B6 bone marrow (top) and one bm1<sup>+</sup> WT OvaFla mouse that received <italic>batf3<sup>–/–</sup></italic> bone marrow (bottom).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72082-fig5-figsupp2-v2.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>Representative histograms demonstrating the dilution of CellTrace Violet dye of OT-Is from individual mice shown in <xref ref-type="fig" rid="fig5">Figure 5D</xref>.</title><p>OT-Is are gated per <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72082-fig5-figsupp3-v2.tif"/></fig><fig id="fig5s4" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 4.</label><caption><title>No difference in the percent of CD62L<sup>–</sup>CD444<sup>+</sup> OT-I T cells or in the TNFα and IFNγ production between genotypes of bm1<sup>+</sup> OvaFla mice.</title><p>(<bold>A</bold>) Percent of OT-Is that are CD62L<sup>–</sup> CD44<sup>+</sup> in the spleen (left) and mesenteric lymph nodes (right). (<bold>B</bold>) Percent of OT-Is from the mesenteric lymph node that are IFNγ<sup>+</sup>TNFα<sup>+</sup> following a 5 hr ex vivo stimulation with phorbol myristate acetate (PMA) (1 μg/mL) and ionomycin (1 μg/mL). Tissues were harvested and analyzed at day 5 post tamoxifen chow start. Samples with fewer than 20 OT-Is were excluded from CD62L, CD44, and cytokine calculations. (A) Data are pooled from three biological replicates. (B) Data are pooled from two biological replicates. Each dot represents an individual mouse. Data shown as mean ± SD. Significance calculated using one-way ANOVA and Šídák’s multiple comparisons test (*p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001). See <xref ref-type="supplementary-material" rid="fig5s4sdata1">Figure 5—figure supplement 4—source data 1</xref> for exact p values.</p><p><supplementary-material id="fig5s4sdata1"><label>Figure 5—figure supplement 4—source data 1.</label><caption><title>Statistical data for <xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-72082-fig5-figsupp4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72082-fig5-figsupp4-v2.tif"/></fig></fig-group><p>To our surprise, there was no difference in the relative (<xref ref-type="fig" rid="fig5">Figure 5B–C</xref>, top) or total (<xref ref-type="fig" rid="fig5">Figure 5B–C</xref>, middle) number of OT-I T cells between bm1<sup>+</sup> WT OvaFla mice that received B6 CD45.1 or <italic>Batf3<sup>–/–</sup></italic> bone marrow in either the spleen or mesenteric lymph node. OT-I T cells in these two mouse groups also appeared to proliferate similarly (<xref ref-type="fig" rid="fig5">Figure 5D</xref>, <xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3</xref>). Additionally, there was no difference in the percent (<xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4</xref>) or total number (<xref ref-type="fig" rid="fig5">Figure 5B–C</xref>, bottom) of CD44<sup>+</sup> CD62L<sup>–</sup> OT-I T cells. These data suggest a <italic>Batf3</italic>-independent population of DCs are responsible for cross-presentation of IEC-derived antigen following NAIP–NLRC4 activation.</p><p>The above findings with WT OvaFla mice are in stark contrast to the <italic>Nlrc4<sup>–/–</sup></italic> OvaFla mice, which exhibit a significant decrease in the relative (<xref ref-type="fig" rid="fig5">Figure 5B–C</xref>, top) and total (<xref ref-type="fig" rid="fig5">Figure 5B–C</xref>, middle) number of OT-I T cells in the spleens and mesenteric lymph nodes of mice that received <italic>Batf3<sup>–/–</sup></italic> donor cells compared to the mice that received B6 CD45.1 donor cells. There was a corresponding significant decrease in the total number of CD44<sup>+</sup> CD62L<sup>–</sup> OT-I T cells (<xref ref-type="fig" rid="fig5">Figure 5B–C</xref>, bottom). The difference in OT-I numbers between these two groups of mice may be related to a relative decrease in proliferation of the OT-I T cells in the mice receiving <italic>Batf3<sup>–/–</sup></italic> bone marrow, as evidenced by less dilution of the CellTrace Violet dye (<xref ref-type="fig" rid="fig5">Figure 5D</xref>, <xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3</xref>). These data indicate that in the absence of NAIP–NLRC4 inflammasome activation, efficient cross-presentation of IEC-derived antigen in vivo requires XCR1<sup>+</sup> cDC1s, but that this requirement is circumvented when the inflammasome is activated.</p><p>NAIP–NLRC4 activation might promote alternative (cDC1-independent) cross-presentation pathways by the pyroptotic release of antigen and/or inflammatory cytokines. To test whether gasdermin D is required for cDC1-independent cross-priming, we examined bm1<sup>+</sup><italic>Gsdmd<sup>–/–</sup></italic> chimeras reconstituted with <italic>Batf3</italic><sup>+</sup> or <italic>Batf3</italic><sup>–/–</sup> bone marrow. The bm1<sup>+</sup> <italic>Gsdmd<sup>–/–</sup></italic> OvaFla mice exhibit a phenotype that falls between the bm1<sup>+</sup> WT and bm1<sup>+</sup> <italic>Nlrc4<sup>–/–</sup></italic> OvaFla mice, with the only significant differences between WT and <italic>Batf3<sup>–/–</sup></italic> bone marrow recipients in the division of OT-I T cells (<xref ref-type="fig" rid="fig5">Figure 5D</xref>, <xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3</xref>) and relative percent of OT-I T cells in the spleen (<xref ref-type="fig" rid="fig5">Figure 5B</xref>, top). These data suggest that the role for NAIP–NLRC4 activation in promoting <italic>Batf3</italic>-independent cross-presentation is minimally driven by IEC pyroptosis.</p><p>Regardless of the bone marrow donor, OT-I T cells in the bm1<sup>+</sup> WT, bm1<sup>+</sup> <italic>Gsdmd<sup>–/–</sup></italic>, and bm1<sup>+</sup> <italic>Nlrc4<sup>–/–</sup></italic> OvaFla mice all showed similar levels of TNFα and IFNγ production following ex vivo stimulation with PMA and ionomycin (<xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4B</xref>). However, when we looked at CCR9 expression as a readout of whether the OT-I T cells were homing to the intestine (<xref ref-type="bibr" rid="bib75">Svensson et al., 2002</xref>), we found a significant decrease in the number of cells expressing CCR9 in the <italic>Batf3<sup>–/–</sup></italic> recipients relative to the B6 CD45.1 recipients across all three mouse lines (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). These data align with previous findings that show that cDC1s play a key role in driving CCR9 expression on CD8<sup>+</sup> T cells (<xref ref-type="bibr" rid="bib37">Joeris et al., 2021</xref>). In summary, our data indicate the existence of two potential pathways by which IEC-derived antigens are cross-presented to CD8<sup>+</sup> T cells: a constitutive pathway that operates in the absence of inflammasome activation that requires <italic>Batf3<sup>+</sup></italic> cDC1s, and a pathway that operates in the presence of inflammasome activation that does not require <italic>Batf3<sup>+</sup></italic> cDC1s. Interestingly, the <italic>Batf3<sup>+</sup></italic> cDC1s appear necessary for instructing antigen-specific CD8<sup>+</sup> T cells back to the intestine.</p></sec><sec id="s2-5"><title>cDCs are required for cross-presentation of IEC-derived antigen</title><p>Although XCR1-expressing cDC1s are the dominant cross-presenting cell type (<xref ref-type="bibr" rid="bib2">Bachem et al., 2012</xref>; <xref ref-type="bibr" rid="bib18">Dorner et al., 2009</xref>), other APCs are reportedly capable of cross-priming CD8<sup>+</sup> T cells as well. These APCs include monocyte-derived DCs (moDCs) (<xref ref-type="bibr" rid="bib4">Briseño et al., 2016</xref>) and red pulp macrophages (<xref ref-type="bibr" rid="bib21">Enders et al., 2020</xref>). Additionally, cDC2s have been show to acquire characteristics of cDC1s under inflammatory conditions (<xref ref-type="bibr" rid="bib3">Bosteels et al., 2020</xref>) or in the absence of <italic>Batf3</italic> (<xref ref-type="bibr" rid="bib47">Lukowski et al., 2021</xref>), though it remains uncertain if these cells are able to cross-prime CD8<sup>+</sup> T cells or provide T cells with the appropriate homing signals.</p><p>To determine whether our <italic>Batf3</italic>-independent cross-presenting population was another cDC population (e.g., cDC2s) or a macrophage or moDC population, we conducted a modified version of the above chimera experiments in which we compared bm1<sup>+</sup> OvaFla mice that received bone marrow from either B6 CD45.1 mice or <italic>Zbtb46-</italic>DTR (diphtheria toxin [DT] receptor) mice (<xref ref-type="bibr" rid="bib54">Meredith et al., 2012</xref>). <italic>Zbtb46</italic> is a transcription factor that drives development of cDCs but not moDCs, macrophages or any other myeloid cell populations (<xref ref-type="bibr" rid="bib54">Meredith et al., 2012</xref>; <xref ref-type="bibr" rid="bib68">Satpathy et al., 2012</xref>). Insertion of the DTR gene into the 3’ untranslated region of <italic>Zbtb46</italic> allows for targeted ablation of these cells in bone marrow chimeras following DT treatment (<xref ref-type="bibr" rid="bib54">Meredith et al., 2012</xref>). Eight weeks post bone marrow reconstitution, all mice were given DT 1 day prior to OT-I transfer and tamoxifen chow pulse and again 3 days later. As before, spleens and mesenteric lymph nodes were collected at day 5 post tamoxifen treatment and analyzed for evidence of cross-primed OT-I CD8<sup>+</sup> T cells.</p><p>When we compared the <italic>Zbtb46</italic><sup>+</sup> (B6) bone marrow recipients with the <italic>Zbtb46</italic>-DTR bone marrow recipients, we found a significant reduction of cDC1s and cDC2s in the mesenteric lymph nodes (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplements 1</xref> and <xref ref-type="fig" rid="fig6s2">2</xref>). Furthermore, both the relative (<xref ref-type="fig" rid="fig6">Figure 6A–B</xref>, top) and total (<xref ref-type="fig" rid="fig6">Figure 6A–B</xref>, bottom) numbers of OT-Is were significantly reduced in the mice that received <italic>Zbtb46</italic>-DTR bone marrow across all WT, <italic>Gsdmd<sup>–/–</sup></italic>, and <italic>Nlrc4<sup>–/–</sup></italic> OvaFla mice. These data demonstrate that the <italic>Batf3</italic>-independent population of cross-presenting cells seen in the WT OvaFla mice in <xref ref-type="fig" rid="fig5">Figure 5</xref> are dependent on <italic>Zbtb46</italic> and thus are likely due to a non-cDC1 subset (presumably cDC2s).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Cross-presentation of intestinal epithelial cell (IEC)-derived antigen is dependent on cDCs.</title><p>(<bold>A</bold>) Quantification of OT-Is as a percent of total CD8<sup>+</sup> T cells (top) and the total number of OT-Is (bottom) in the spleen. (<bold>B</bold>) Quantification of OT-Is as a percent of total CD8<sup>+</sup> T cells (top) and the total number of OT-Is (bottom) in the mesenteric lymph nodes. All mice were given two doses of diphtheria toxin (DT) (see Materials and methods), and tissues were harvested and analyzed at day 5 post tamoxifen chow start. Data are pooled from two biological replicates. Data shown as mean ± SD. Significance calculated using one-way ANOVA and Šídák’s multiple comparisons test (*p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001). See <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref> for exact p values.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Statistical data for <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-72082-fig6-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72082-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Gating strategy to identify conventional type one dendritic cells (cDC1s) and cDC2s in chimeric bm1<sup>+</sup> OvaFla mice that received bone marrow from either B6 mice (top) or Zbtb46–DTR mice (bottom).</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72082-fig6-figsupp1-v2.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Injection of diphtheria toxin (DT) results in the depletion of conventional type one dendritic cells (cDC1s) and cDC2s from chimeric bm1<sup>+</sup> OvaFla mice given Zbtb46–DTR bone marrow.</title><p>Percent of CD45<sup>+</sup> cells in the mesenteric lymph node that are cDC1 (left) or cDC2 (right) from two separate experiments. See <xref ref-type="supplementary-material" rid="fig6s2sdata1">Figure 6—figure supplement 2—source data 1</xref> for exact p values.</p><p><supplementary-material id="fig6s2sdata1"><label>Figure 6—figure supplement 2—source data 1.</label><caption><title>Statistical data for <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-72082-fig6-figsupp2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72082-fig6-figsupp2-v2.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>IECs represent an important barrier surface that protects against enteric pathogens. At the same time, IECs also represent a potential replicative niche for pathogens. As such, the immune system must survey IECs for foreign antigens and present those antigens to activate protective adaptive immune responses. In general, it remains poorly understood whether and how IEC-derived antigens are presented to activate T cell responses. In particular, the relative contributions of direct versus cross-presentation of IEC antigens to CD8<sup>+</sup> T cells have not been thoroughly investigated. Here, we employed a genetic system that inducibly expresses a model antigen (ovalbumin) fused to an NAIP–NLRC4 agonist (flagellin) within the cytosol of cells (<xref ref-type="bibr" rid="bib58">Nichols et al., 2017b</xref>). We crossed these ‘OvaFla’ mice to Villin-Cre-ER<sup>T2</sup> mice, allowing for tamoxifen-inducible expression specifically in IECs. By additionally crossing to an H-2K<sup>bm1</sup> background (<xref ref-type="bibr" rid="bib59">Nikolić-Zugić and Bevan, 1990</xref>; <xref ref-type="bibr" rid="bib70">Schulze et al., 1983</xref>), and using the resulting mice as irradiated recipients for WT K<sup>b</sup> hematopoietic donor cells, we engineered a system in which an IEC-derived ovalbumin antigen (SIINFEKL) cannot be directly presented to OT-I T cells but can still be acquired by hematopoietic cells and cross-presented. Using this system, we established in vivo that there is an antigen presentation pathway in which IEC-derived antigens are cross-presented to activate CD8<sup>+</sup> T cells. This finding extends previous work indicating that ex vivo isolated DCs can cross-present IEC-derived antigens to CD8<sup>+</sup> T cells (<xref ref-type="bibr" rid="bib8">Cerovic et al., 2015</xref>; <xref ref-type="bibr" rid="bib12">Cummings et al., 2016</xref>). We show that these antigens can activate antigen-specific CD8<sup>+</sup> T cells in vivo, and that this activation can occur even when direct presentation is genetically eliminated. We suggest that the cross-presentation pathway revealed by our analyses could be of importance during infection with pathogens that replicate in IECs, though future studies will be required to evaluate this hypothesis.</p><p>Our genetic system also allowed us to assess the contribution of IEC inflammasome activation to the adaptive immune response. Inflammasomes are a critical component of the innate immune response to many pathogens, and their activation is known to influence adaptive immunity (<xref ref-type="bibr" rid="bib16">Deets and Vance, 2021</xref>). However, in previous studies, it has been difficult to isolate the specific effects of inflammasome activation on adaptive immunity because microbial pathogens activate numerous innate immune signaling pathways over the course of an infection. By providing a genetically encoded antigen and inflammasome stimulus, we were able to overcome this issue and specifically address the role of inflammasomes in adaptive CD8<sup>+</sup> T cell responses in vivo. We crossed our OvaFla Villin-Cre-ER<sup>T2</sup> mice to mice deficient in key inflammasome components. Consistent with previous work, we found that <italic>Nlrc4</italic><sup>–/–</sup> mice entirely lack the inflammasome response to cytosolic flagellin, whereas <italic>Pycard</italic><sup>–/–</sup> mice are defective for IL-18 release but not pyroptotic cell death or IEC expulsion (<xref ref-type="bibr" rid="bib67">Rauch et al., 2017</xref>; <xref ref-type="fig" rid="fig1">Figures 1C, E</xref>, <xref ref-type="fig" rid="fig2">2B</xref>). We also crossed OvaFla Villin-Cre-ER<sup>T2</sup> mice to pyroptosis-deficient <italic>Gsdmd</italic><sup>–/–</sup> mice and found that they were defective for IL-18 release in vivo (<xref ref-type="fig" rid="fig1">Figure 1C and E</xref>).</p><p>Because <italic>Nlrc4<sup>–/–</sup></italic> IECs fail to undergo pyroptosis or IEC expulsion (<xref ref-type="bibr" rid="bib67">Rauch et al., 2017</xref>), we noted that cells expressing the OvaFla transgene accumulate to much higher levels in the <italic>Nlrc4</italic><sup><italic>–/–</italic></sup> mice than in WT, <italic>Pycard</italic><sup>–/–</sup>, or <italic>Gsdmd</italic><sup>–/–</sup> mice, in which IEC expulsion still occurs (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Higher levels of Ova antigen in IECs has previously found to correlate with higher levels of OT-I expansion in the spleen and mesenteric lymph nodes of mice (<xref ref-type="bibr" rid="bib79">Vezys et al., 2000</xref>). Because of the differences in antigen level, comparisons of <italic>Nlrc4</italic><sup><italic>–/–</italic></sup> mice to the other genotypes must be made with caution. Nevertheless, we found that OT-I T cells in the <italic>Nlrc4<sup>–/–</sup></italic> OvaFla mice divide and are activated at similar levels to the WT OvaFla mice following tamoxifen administration (<xref ref-type="fig" rid="fig3">Figure 3B–D</xref>). This activation occurred even when direct presentation of the OT-I peptide by IECs was eliminated on the K<sup>bm1</sup> background (<xref ref-type="fig" rid="fig4">Figure 4B–C</xref>). These results are surprising for two reasons. First, it is not clear how IEC-derived antigens would be delivered to APCs in the absence of inflammasome-induced cell death. Other studies have suggested that IEC apoptosis, which may occur during homeostatic IEC turnover (<xref ref-type="bibr" rid="bib7">Bullen et al., 2006</xref>; <xref ref-type="bibr" rid="bib27">Hall et al., 1994</xref>; <xref ref-type="bibr" rid="bib50">Marshman et al., 2001</xref>; <xref ref-type="bibr" rid="bib74">Shibahara et al., 1995</xref>; <xref ref-type="bibr" rid="bib81">Watson et al., 2005</xref>), can be a source of antigen for T cell activation (<xref ref-type="bibr" rid="bib12">Cummings et al., 2016</xref>; <xref ref-type="bibr" rid="bib34">Huang et al., 2000</xref>). However, apoptotic IECs are expelled apically into the intestinal lumen (<xref ref-type="bibr" rid="bib7">Bullen et al., 2006</xref>; <xref ref-type="bibr" rid="bib27">Hall et al., 1994</xref>; <xref ref-type="bibr" rid="bib50">Marshman et al., 2001</xref>; <xref ref-type="bibr" rid="bib74">Shibahara et al., 1995</xref>; <xref ref-type="bibr" rid="bib81">Watson et al., 2005</xref>), and so the exact mechanism of basolateral antigen delivery remains unclear—though it may involve luminal sampling by intestinal phagocytes (<xref ref-type="bibr" rid="bib25">Farache et al., 2013</xref>) and/or the transfer of plasma membrane components (trogocytosis) (<xref ref-type="bibr" rid="bib14">Dance, 2019</xref>). Cummings et al. suggested that IECs can be engulfed by APCs, resulting in antigen presentation on MHC class II to induce CD4<sup>+</sup> T regulatory cells, but this work did not examine antigen-specific responses or MHC class I presentation to CD8<sup>+</sup> T cells. Additionally, Joeris et al. recently showed that cDC1s can present IEC-derived self-antigen to drive cross-tolerant OT-I T cells (<xref ref-type="bibr" rid="bib37">Joeris et al., 2021</xref>). Further work is therefore needed to understand mechanisms of IEC-derived antigen presentation in the absence of inflammatory cell death. The second reason we were surprised to see CD8<sup>+</sup> T cell activation in <italic>Nlrc4</italic><sup>–/–</sup> OvaFla mice is that these mice are presumably unable to produce inflammatory signals necessary to induce APC activation. However, previous studies have shown that OT-I T cells can be activated from constitutively expressed Ova in the absence of inflammation. In this scenario, the CD8<sup>+</sup> T cells go on to become anergic and are likely eventually deleted from the periphery (<xref ref-type="bibr" rid="bib42">Kurts et al., 1996</xref>; <xref ref-type="bibr" rid="bib43">Kurts et al., 1997</xref>; <xref ref-type="bibr" rid="bib46">Liu et al., 2007</xref>; <xref ref-type="bibr" rid="bib79">Vezys et al., 2000</xref>).</p><p>Since WT, <italic>Pycard</italic><sup>–/–</sup>, and <italic>Gsdmd</italic><sup>–/–</sup> IECs all undergo cell death and IEC expulsion in response to NLRC4 activation, these mice exhibit similar levels of OvaFla transgene expression in IECs, allowing for comparisons between these mouse strains (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). We found that OvaFla production leads to CD8<sup>+</sup> T cell expansion and activation in all of these strains. The expansion is at least partially dependent on gasdermin D, as <italic>Gsdmd<sup>–/–</sup></italic> OvaFla mice have significantly fewer OT-I T cells than their WT counterparts (<xref ref-type="fig" rid="fig3">Figure 3B and C</xref>). Interestingly, ASC-deficient OvaFla mice—in which IECs still undergo pyroptosis following NAIP–NLRC4 activation (<xref ref-type="bibr" rid="bib66">Rauch et al., 2016</xref>)—show similar, or even increased, OT-I numbers in their tissues relative to WT OvaFla mice (<xref ref-type="fig" rid="fig3">Figure 3B and C</xref>). These data, combined with the fact that <italic>Gsdmd<sup>–/–</sup></italic> and <italic>Pycard<sup>–/–</sup></italic> OvaFla mice have little to no detectable IL-18 in their serum (<xref ref-type="fig" rid="fig1">Figure 1C and E</xref>), suggest that the difference in OT-I T cell proliferation between these strains is in some way related to pyroptotic antigen release. One hypothesis is that the gasdermin D pore, which has been shown to provide a lysis-independent portal for IL-1β, IL-18, and other small proteins (<xref ref-type="bibr" rid="bib17">DiPeso et al., 2017</xref>; <xref ref-type="bibr" rid="bib24">Evavold et al., 2018</xref>; <xref ref-type="bibr" rid="bib30">Heilig et al., 2018</xref>), may act as a channel for small antigens to escape IECs prior to cell expulsion.</p><p>Because <italic>Gsdmd</italic> deficiency only modestly affected OT-I responses, our data additionally suggest that there may be both GSDMD-dependent and GSDMD-independent pathways by which IEC antigens can be cross-presented to CD8<sup>+</sup> T cells. Because <italic>Batf3<sup>–/–</sup></italic>-dependent cDC1s have a known role in cross-presenting IEC-derived antigen (<xref ref-type="bibr" rid="bib8">Cerovic et al., 2015</xref>), we sought to determine if the cross-presentation occurring in the OvaFla mice similarly relied on these cells. We compared bm1<sup>+</sup> OvaFla mice that received B6 CD45.1 bone marrow with those that received bone marrow from <italic>Batf3</italic>-deficient mice (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). To our surprise, we found OT-I T cells were cross-primed in the bm1<sup>+</sup> WT OvaFla mice, even in the recipients that lacked cDC1s (<xref ref-type="fig" rid="fig5">Figure 5A–D</xref>). Interestingly, these data contrast with the bm1<sup>+</sup> <italic>Nlrc4<sup>–/–</sup></italic> OvaFla mice, where the recipients given <italic>Batf3</italic>-deficient bone marrow had significantly fewer activated OT-I T cells than their counterparts given <italic>Batf3</italic>-sufficient bone marrow. OT-I T cell activation in the bm1<sup>+</sup> <italic>Gsdmd<sup>–/–</sup></italic> OvaFla mice partially relied on <italic>Batf3</italic><sup>+</sup> DCs. Furthermore, CellTrace Violet data show the OT-I T cells in the bm1<sup>+</sup> <italic>Nlrc4<sup>–/–</sup></italic> and bm1<sup>+</sup> <italic>Gsdmd<sup>–/–</sup></italic> OvaFla mice undergo fewer rounds of division in the absence of <italic>Batf3</italic> cDC1s (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). These data suggest there may be two possible cross-presentation pathways for IEC-derived antigen: one that occurs in the presence, and one in the absence, of inflammasome-derived inflammatory signals. We found that <italic>Zbtb46</italic><sup>+</sup> bone marrow-derived cells were required for both pathways (<xref ref-type="fig" rid="fig6">Figure 6</xref>), indicating that cross-presentation seen under inflammatory conditions occurs through a <italic>Batf3</italic>-independent but <italic>Zbtb46</italic>-dependent cDC population. We hypothesize that these cells are cDC2s, as recent work shows that cDC2s can take on characteristics of cDC1s under inflammatory conditions (<xref ref-type="bibr" rid="bib3">Bosteels et al., 2020</xref>) or in the absence of <italic>Batf3</italic> (<xref ref-type="bibr" rid="bib47">Lukowski et al., 2021</xref>).</p><p>Our work raises several interesting questions for future study, including the mechanism of cDC maturation. The traditional model of DC maturation involves TLR signaling on the DC (<xref ref-type="bibr" rid="bib13">Dalod et al., 2014</xref>). IL-1R (<xref ref-type="bibr" rid="bib64">Pang et al., 2013</xref>) or IL-18R (<xref ref-type="bibr" rid="bib44">Li et al., 2004</xref>) on these cells might also trigger maturation, though further investigation is needed to understand how IL-1β, IL-18, or other inflammatory signals, such as eicosanoids (<xref ref-type="bibr" rid="bib53">McDougal et al., 2021</xref>; <xref ref-type="bibr" rid="bib61">Oyesola et al., 2021</xref>; <xref ref-type="bibr" rid="bib67">Rauch et al., 2017</xref>), downstream of inflammasome activation might drive maturation of DCs that have acquired IEC-derived antigen.</p><p>Overall, our studies show that IEC-derived antigens are cross-presented both following NAIP–NLRC4 activation and under apparent homeostatic conditions in the absence of NAIP–NLRC4-induced inflammation. In the context of NAIP–NLRC4 activation, cross-priming of CD8<sup>+</sup> T cells is partially dependent on gasdermin D-mediated pyroptosis and requires a <italic>Batf3</italic>-independent cDC population. These data add insights to the complex interactions between innate and adaptive immune responses occurring in the intestine.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Gene (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>Nlrc4</italic></td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">Gene ID: 268973</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Gene (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>Gsdmd</italic></td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">Gene ID: 69146</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Gene (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>Pycard</italic></td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">Gene ID: 66824</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Gene (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>Batf3</italic></td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">Gene ID: 55509</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Gene (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>Zbtb46</italic></td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">Gene ID: 72147</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>Nlrc4<sup>–/–</sup></italic></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/15190255/">15190255</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:MGI:3047280">MGI:3047280</ext-link></td><td align="left" valign="bottom">Vishva Dixit, Genentech, South San Francisco, CA</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>Gsdmd<sup>–/–</sup></italic></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/28410991/">28410991</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:032663">IMSR_JAX:032663</ext-link></td><td align="left" valign="bottom">Generated via CRISPR/Cas9 from UC Berkeley Gene Targeting Facility</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>Pycard<sup>–/–</sup></italic></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/15190255/">15190255</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:MGI:3047277">MGI:3047277</ext-link></td><td align="left" valign="bottom">Vishva Dixit, Genentech, South San Francisco, CA</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>Batf3<sup>–/–</sup></italic></td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:013755">IMSR_JAX:013755</ext-link></td><td align="left" valign="bottom">C57BL/6J background</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>Zbtb46<sup>–/–</sup></italic></td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:019506">IMSR_JAX:019506</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Villin-Cre-ER<sup>T2</sup></td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:020282">IMSR_JAX:020282</ext-link></td><td align="left" valign="bottom">C57BL/6NJ background</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">OT-I <italic>Rag2<sup>–/–</sup></italic></td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:003831">IMSR_JAX:003831</ext-link></td><td align="left" valign="bottom">C57BL/6 background</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">OvaFla</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/29263322/">29263322</ext-link></td><td align="left" valign="bottom">MGI:6196853</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD16/CD32 Purified (rat monoclonal)</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Clone: 93; Cat#: 14-0161-85</td><td align="left" valign="bottom">FC(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD45.1 APC (mouse monoclonal)</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Clone: A20; Cat#: 17-0453-81</td><td align="left" valign="bottom">FC(1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD45 APC (rat monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Clone: 30-F11; Cat#: 103111</td><td align="left" valign="bottom">FC(1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD45.2 PE/Cy7 (mouse monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Clone: 104; Cat#: 109830</td><td align="left" valign="bottom">FC(1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD8a Brilliant Violet 650 (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Clone: 53–6.7; Cat#: 100742</td><td align="left" valign="bottom">FC(1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD44 BB515 (rat monoclonal)</td><td align="left" valign="bottom">BD</td><td align="left" valign="bottom">Clone: IM9; Cat#: 564587</td><td align="left" valign="bottom">FC(1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD62L Brilliant Violet 711 (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Clone: MEL-14; Cat#: 104445</td><td align="left" valign="bottom">FC(1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD199 (CCR9) PE (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Clone: 9B1; Cat#: 129707</td><td align="left" valign="bottom">FC(1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse TNFa FITC (mouse monoclonal)</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Clone: MP6-XT22; Cat#: 11-7321-82</td><td align="left" valign="bottom">FC(1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD11c PE (arm hamster monoclonal)</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Clone: 418; Cat#: 12-0114-81</td><td align="left" valign="bottom">FC(1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse MHC Class II (I-A/I-E) APC-eFluor 780 (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Clone: M5/114.15.2; Cat#: 107628</td><td align="left" valign="bottom">FC(1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD4 APC/Fire 750 (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Clone: GK1.5; Cat#: 100460</td><td align="left" valign="bottom">FC(1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Mouse CD11b PE-Cyanine7 (rat monoclonal)</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Clone: M1/70; Cat#: 25-0112-81</td><td align="left" valign="bottom">FC(1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD11c Brilliant Violet 711 (arm hamster monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Clone: N418; Cat#: 117349</td><td align="left" valign="bottom">FC(1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD45 Brilliant Violet 785(rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Clone: 30-F11; Cat#: 103149</td><td align="left" valign="bottom">FC(1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse MHC II I-A/I-E FITC (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Clone: M5/114.15.2; Cat#: 107605</td><td align="left" valign="bottom">FC(1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse/rat XCR1 APC (mouse monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Clone: ZET; Cat#: 148206</td><td align="left" valign="bottom">FC(1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD90.2 (Thy-1.2) APC/Fire 750 (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Clone: 53–2.1; Cat#: 140326</td><td align="left" valign="bottom">FC(1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse Ly-6G/Ly-6C (Gr-1) APC/Cyanine7 (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Clone: Gr1; Cat#: 108424</td><td align="left" valign="bottom">FC(1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD64 (FcγRI) APC (mouse monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Clone: X54-5/7.1; Cat#: 139306</td><td align="left" valign="bottom">FC(1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD45.2 PerCP-Cyanine5.5 (mouse monoclonal)</td><td align="left" valign="bottom">eBio</td><td align="left" valign="bottom">Clone: 45-0454-82; Cat#: 17-0454-82</td><td align="left" valign="bottom">FC(1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse MHC Class II (I-A/I-E) FITC (rat monoclonal)</td><td align="left" valign="bottom">Fisher</td><td align="left" valign="bottom">Clone: M5/114.15.2; Cat#: 11-5321-82</td><td align="left" valign="bottom">FC(1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD64 PE (mouse monoclonal)</td><td align="left" valign="bottom">Fisher</td><td align="left" valign="bottom">Clone: X54-5/7.1; Cat#: 12-0641-82</td><td align="left" valign="bottom">FC(1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD45.2 PE (mouse monoclonal)</td><td align="left" valign="bottom">Fisher</td><td align="left" valign="bottom">Clonne: 104; Cat#: 12-0454-82</td><td align="left" valign="bottom">FC(1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD11b PE-Cyanine7 (rat monoclonal)</td><td align="left" valign="bottom">Fisher</td><td align="left" valign="bottom">Clone: M1/70; Cat#: 25-0112-82</td><td align="left" valign="bottom">FC(1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD90.2 (Thy-1.2) Pacific Blue (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Clond: 53–2.1; Cat#: 140306</td><td align="left" valign="bottom">FC(1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD86 Brilliant Violet 785 (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Clone: GL-1; Cat#: 105043</td><td align="left" valign="bottom">FC(1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD172a (SIRPα) Brilliant Violet 510 (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Clone: P84; Cat#: 144032</td><td align="left" valign="bottom">FC(1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Ghost Dye Red 780</td><td align="left" valign="bottom">Tonbo</td><td align="left" valign="bottom">Cat#: 13–0865T500</td><td align="left" valign="bottom">FC(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-rabbit IgG (H + L) AF 488 (donkey polyclonal)</td><td align="left" valign="bottom">Jackson Immunoresearch</td><td align="left" valign="bottom">Cat#: 711-545-152</td><td align="left" valign="bottom">IF(1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse GFP Polyclonal Antibody (rabbit polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat#: A-6455</td><td align="left" valign="bottom">IF(1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse IL-18 Biotin (rat monoclonal)</td><td align="left" valign="bottom">MBL</td><td align="left" valign="bottom">Clone: 93–10 C; Cat#: D048-6</td><td align="left" valign="bottom">ELISA(1 µg/mL)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse IL-18 (rat monoclonal)</td><td align="left" valign="bottom">BioXcell</td><td align="left" valign="bottom">Clone: YIGIF74-1G7; Cat#: BE0237</td><td align="left" valign="bottom">ELISA(1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD3 biotin (arm ham monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Clone:145–2 C11; Cat#: 100304</td><td align="left" valign="bottom">For depletion, 10 µL/10<sup>7</sup> cells</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">BD Pharmingen Streptavidin HRP</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2868972">AB_2868972</ext-link>; Cat#: 554066</td><td align="left" valign="bottom">ELISA(1:1000)</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">CellTrace Violet Cell Proliferation Kit</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat#: C34557</td><td align="left" valign="bottom">See Materials and methods section; 1 µL/10<sup>6</sup> cells</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Anti-Biotin MicroBeads</td><td align="left" valign="bottom">Miltenyi</td><td align="left" valign="bottom">Cat#: 130-105-637</td><td align="left" valign="bottom">For depletion, 20 µL/10<sup>7</sup> cells</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">LD Columns</td><td align="left" valign="bottom">Miltenyi</td><td align="left" valign="bottom">Cat#: 130-042-901</td><td align="left" valign="bottom">See Materials and methods section</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">DAPI</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat#: D1306</td><td align="left" valign="bottom">IF(10 nM)</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">BD GolgiPlug</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat#: 555029</td><td align="left" valign="bottom">FC(1:1000)</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Phorbol myristate acetate (PMA)</td><td align="left" valign="bottom">Invivogen</td><td align="left" valign="bottom">Cat#: tlrl-pma</td><td align="left" valign="bottom">FC(1 µg/mL)</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Ionomycin</td><td align="left" valign="bottom">Calbiochem</td><td align="left" valign="bottom">Cat#: 407952–1MG</td><td align="left" valign="bottom">FC(1 µg/mL)</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom"><italic>o</italic>-Phenylenediamine dihydrochloride</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat#: P3804-100TAB</td><td align="left" valign="bottom">ELISA(one tab/ 5 mL)</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Tamoxifen chow</td><td align="left" valign="bottom">envigo</td><td align="left" valign="bottom">Cat#: 130856</td><td align="left" valign="bottom">See Materials and methods section</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Diphtheria toxin from <italic>Corynebacterium diphtheriae</italic></td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat#: D0564-1MG</td><td align="left" valign="bottom">See Materials and methods section</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ImageJ</td><td align="left" valign="bottom">NIH</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_003070">SCR_003070</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">FlowJo</td><td align="left" valign="bottom">BD</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_008520">SCR_008520</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Prism</td><td align="left" valign="bottom">GraphPad</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002798">SCR_002798</ext-link></td><td align="left" valign="bottom"> </td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Animals</title><p>All mice were maintained under specific pathogen-free conditions and, unless otherwise indicated, fed a standard chow diet (Harlan irradiated laboratory animal diet) ad libitum. OvaFla mice were generated as previously described (<xref ref-type="bibr" rid="bib58">Nichols et al., 2017b</xref>) and crossed to Villin-Cre-ER<sup>T2</sup>, which we obtained from Avril Ma (UCSF, San Francisco, CA) (<xref ref-type="bibr" rid="bib20">el Marjou et al., 2004</xref>). OvaFla Villin-Cre-ER<sup>T2</sup> mice were additionally bred to <italic>Gsdmd<sup>–/–</sup></italic>, <italic>Pycard<sup>–/–</sup></italic>, and <italic>Nlrc4<sup>–/–</sup></italic> mice. <italic>Nlrc4<sup>–/–</sup></italic> and <italic>Pycard<sup>–/–</sup></italic> mice were from V. Dixit (<xref ref-type="bibr" rid="bib49">Mariathasan et al., 2004</xref>) (Genentech, South San Francisco, CA). <italic>Gsdmd<sup>–/–</sup></italic> mice were previously described (<xref ref-type="bibr" rid="bib67">Rauch et al., 2017</xref>). OT-I <italic>Rag2<sup>–/–</sup></italic> mice (from E Robey, Berkeley, CA) were used as a source of OT-Is for all adoptive transfer experiments.</p><p>For chimera experiments, the above OvaFla lines were crossed to B6.C-<italic>H-2K<sup>bm1</sup></italic>/ByJ mice (<xref ref-type="bibr" rid="bib70">Schulze et al., 1983</xref>) (Jax strain 001060). For the bone marrow donors, B6.CD45.1 (Jax strain 002014), <italic>Batf3<sup>–/–</sup></italic> (Jax strain 013755), and <italic>Zbtb46</italic>–DTR (Jax strain 019506) mice were used.</p><p>Mice used for non-chimera experiments were 8–12 weeks of age upon tissue harvest, and mice used as chimeras were 16–20 of weeks of age upon tissue harvest. Female mice were co-housed, and all experimental mice were age- and sex-matched when possible. OvaFla-only and Cre-only controls were littermates of the experimental mice. All animal experiments and endpoints were approved by and performed in accordance with the regulations of the University of California Berkeley Institutional Animal Care and Use Committee.</p></sec><sec id="s4-2"><title>Adoptive transfer of OT-I T cells</title><p>The spleen and mesenteric lymph nodes were harvested from OT-I <italic>Rag2</italic><sup>–/–</sup> mice, mashed between the frosted ends of two glass slides to create a single cell suspension, filtered through 100 μm nylon mesh, and pooled into a single tube. Red blood cells were lysed with ACK Lysing Buffer (Gibco; A10492-01). Cells were labeled with CellTrace Violet (ThermoFisher; C34557) following the manufacturer’s protocol and transferred i.v. to mice anesthetized with isoflurane at 2 × 10<sup>4</sup> cells per mouse.</p></sec><sec id="s4-3"><title>Tamoxifen administration</title><p>The tamoxifen chow used in these studies was purchased from Envigo (<ext-link ext-link-type="uri" xlink:href="https://www.envigo.com/tamoxifen-custom-diets">https://www.envigo.com/tamoxifen-custom-diets</ext-link>; 120856). The diet contains 250 mg of tamoxifen per kilogram of chow and was irradiated prior to shipping. Mice were fed ab libitum for 2 days for the experiments in <xref ref-type="fig" rid="fig1">Figure 1B–C</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref> and 1 day for the remaining experiments. Envigo assumes approximately 40 mg of tamoxifen is consumed per kilogram of body weight per day for each mouse, though feed aversion leads to variable and limited initial food intake (<xref ref-type="bibr" rid="bib9">Chiang et al., 2010</xref>).</p></sec><sec id="s4-4"><title>DT treatment</title><p>To deplete cDCs in the <italic>Zbtb46</italic>–DTR → bm1<sup>+</sup>OvaFla chimeras, all mice were given two doses of DT (Sigma; D-0564) as described in <xref ref-type="bibr" rid="bib54">Meredith et al., 2012</xref>. Each animal was given an initial dose of 20 ng DT per gram body weight 1 day prior to OT-I T cell transfer and tamoxifen chow pulse. The mice were then given a second dose of 4 ng DT per gram body weight 3 days after the initial dose.</p></sec><sec id="s4-5"><title>Flow cytometry</title><p>Spleens and mesenteric lymph nodes were harvested from euthanized mice and stored on ice in T cell media: RMPI 1640 (Gibco; 21870092) containing 10% FBS (Gibco, Cat#16140071, Lot#1447825), 1% penicillin-streptomycin, 1% L-glutamine, 1% sodium pyruvate, 0.5% 2-mercaptoethanol, and 25 mM HEPES. For lymphocyte staining, tissues were mashed between the frosted ends of glass slides and filtered through 100 μm nylon mesh. For myeloid staining, tissues were minced with scissors and forceps and incubated in T cell media containing 1 mg/mL collagenase VIII (Sigma; C2139-1G) or in HBSS (Ca<sup>2+</sup>, Mg<sup>2+</sup>) (Gibco; 14025076) containing DNase I (900 mg/1 mL) (Sigma; DN25-10MG) and Liberase TM (Roche; 5401119001), at 37°C for 25–45 min. The digested tissues were then passed through 70 μm filters and washed with T cell media. For all stains, red blood cells were lysed from a single cell suspension using ACK Lysing Buffer. Cells were counted using a Beckman Vi-CELL XR Cell Viability Analyzer (Beckman Coulter, Brea, CA), and 3 × 10<sup>6</sup> cells per tissue per mouse were added to individual FACS tubes or wells of a 96-well non-tissue culture-treated round bottom plate.</p><p>For extracellular surface staining, cells were blocked for 20–30 min with a 1:1000 dilution of anti-mouse CD16 and CD32 antibodies (eBioscience; 14-0161-85) at 4°C and then stained with a cocktail of antibodies for extracellular markers (Key resource table) at room temperature (RT) for 1 hr. All dilutions and washes were done with 1× PBS (Gibco; 10010049) containing 5% FBS/FCS.</p><p>For intracellular cytokine analysis, cells were incubated at 1 × 10<sup>6</sup> cells/mL T cell media plus 1 μg/mL PMA (Invivogen; tlrl-pma), 1 μg/mL ionomycin (Calbiochem; 407952–1 MG), and 1 μg/mL GolgiPlug (BD Biosciences; 555029) at 37°C for 5 hr. Cells were then washed and blocked for 20–30 min with a 1:1000 dilution of anti-mouse CD16 and CD32 antibodies at 4°C, and a surface stain was applied for 1 hr at RT (see Key resources table). Cells were then fixed in 100 mL eBioscience IC Fixation Buffer (Thermo; 00-8222-49) for 20–60 min RT, and then stained with an intracellular staining cocktail (see Key resources table) in 1× eBioscience Permeabilization Buffer (Thermo; 00-8333-56) at RT for 1 hr. Cells were washed and resuspended in PBS prior to analysis. The data were collected on a BD Biosciences Fortessa (San Jose, CA) in the UC Berkeley Cancer Research Laboratory Flow Cytometry facility, and analysis was performed using FlowJo 10 Software (BD Biosciences, San Jose, CA).</p></sec><sec id="s4-6"><title>Generation of bone marrow chimeras</title><p>Eight- to twelve-week-old mice were lethally irradiated with a Precision X-Rad320 X-ray irradiator (North Branford, CT) using a split dose of 500 rads and then 450 rads, approximately 15 hr apart. Bone marrow was harvested from the long bones of the indicated donor strains, red blood cells were lysed using ACK Lysing Buffer, and CD3<sup>+</sup> cells were depleted from the donor cells using a biotinylated anti-mouse CD3ε mAb (BioLegend; 100304) and the Miltenyi MACS MicroBead (Miltenyi; 130-105-637) magnetic depletion protocol with LD columns (Miltenyi; 130-042-901) to reduce graft versus host reactions (<xref ref-type="bibr" rid="bib72">Selvaggi et al., 1996</xref>). Recipient mice were anesthetized with isoflurane, and approximately 5 × 10<sup>6</sup> donor cells were injected retro-orbitally. Females from the different strains were co-housed, and at least 8 weeks passed between reconstitution and the start of any experiment.</p></sec><sec id="s4-7"><title>Immunofluorescence</title><p>Mice were fed a single day pulse of tamoxifen chow and euthanized 2 days from start of the chow feeding. Approximately 2.5 cm pieces were taken from the proximal and distal ends of the small intestine. These pieces were flushed and fixed in PLP buffer (0.05 M phosphate buffer containing 0.1 M L-lysine [pH 7.4], 2 mg/mL NaIO<sub>4</sub>, and 1% PFA) overnight at 4°C. The following day, tissues were washed 2× in phosphate buffer and placed in 30% sucrose overnight at 4°C. Tissue was frozen in Tissue-Tek OCT (VWR; 25608–930), cut on a Leica cryostat, and sections were placed on Fisherbrand Tissue Path Superfrost Plus Gold Slides (Fisher Scientific; 15-188-48).</p><p>For staining, slides were allowed to warm to RT, traced with an ImmEdge Hydrophobic Barrier Pen (Vector Labs; H-4000), washed 3× in 1× PBS with 0.5% Tween-20, and blocked with 10% normal donkey serum (Sigma; D9663) in 0.5% Tween-20, 100 mM TrisHCl [pH 7.5], 150 mM NaCl, 0.5% blocking reagent (Perkin Elmer; FP1020) for 30 min. Tissues were then stained with 1:300 GFP polyclonal antibody (Invitrogen; A-6455) overnight at 4°C. Slides were washed 3× and stained with donkey anti-rabbit Alexa Fluor 488 (Jackson Immunoresearch; 711-545-152) for 60 min at RT, followed by 150 nM Acti-stain 555 phalloidin (Cytoskeleton, Inc; PHDH1-A) and 100 mM DAPI (D1306) for 30 min at RT. Slides were then washed 2× in H<sub>2</sub>O and sealed under glass coverslips prior to imaging. All antibody dilutions were done in 100 mM TrisHCl [pH 7.5], 150 mM NaCl, 0.5% blocking reagent; all washes were done in 1× PBS with 0.5% Tween-20.</p><p>Slides were imaged on a Zeiss LSM710 at the CNR Biological Imaging Facility at the University of California, Berkeley. Images were blinded and manually quantified for GFP<sup>+</sup> IECs. For quantification of GFP<sup>+</sup> cells, DAPI<sup>+</sup> IECs were counted in at least 15 villi per mouse—DAPI<sup>+</sup> cells were counted prior to revealing the GFP<sup>+</sup> cells in the 488 channel. For quantification of amount GFP levels per IEC, ImageJ (National Institutes of Health) was used to trace and measure the mean pixel intensity in the GFP channel for individual GFP<sup>+</sup> cells, with 12–20 cells per image. ImageJ was used to visualize images and globally adjust contrast and brightness for print quality following quantification.</p></sec><sec id="s4-8"><title>Serum IL-18 measurement</title><p>Thermo Scientific Immuno MaxiSorp ELISA plates (Thermo Fisher; 439454) were coated with 1 μg/mL anti-mouse IL-18 mAb (MBL; D048-6) overnight at 4°C, and blocked with 1× PBS containing 1% BSA for 2–4 hr at RT. Serum was diluted 1:5 in PBS with 1% BSA, added to the plate with a purified IL-18 standard, and incubated overnight at 4°C. A biotinylated anti-mouse IL-18 sandwich mAb (BioXcell; BE0237) was added at 1:2000 in PBS with 1% BSA and incubated for 1–2 hr at RT. BD Pharmingen Streptavidin HRP (BD Biosciences; 554066) was added at 1:1000 in PBS with 1% BSA. Following a final 5× wash, plates were developed with 1 mg/mL OPD (Sigma; P3804-100TAB) in citrate buffer (PBS with 0.05 M NaH<sub>2</sub>PO<sub>4</sub> and 0.02 M citric acid) plus 9.8 M H<sub>2</sub>O<sub>2</sub>. The reaction was stopped with a 3 M HCl acid stop after approximately 10 min. Absorbance at 490 nm was measured on a Tecan Spark multimode microplate reader (Tecan Trading AG, Switzerland).</p></sec><sec id="s4-9"><title>Statistical analysis</title><p>For all bar graphs, data are shown as mean ± SD. For <xref ref-type="fig" rid="fig1">Figures 1</xref>—<xref ref-type="fig" rid="fig4">4</xref>, the significance between each genotype was calculated using one-way ANOVA and Tukey’s multiple comparisons test. For <xref ref-type="fig" rid="fig5">Figure 5</xref>, the significance between mice that received B6 CD45.1 and mice that received <italic>Batf3<sup>–/–</sup></italic> bone marrow was calculated using one-way ANOVA and Šídák’s multiple comparisons test. <xref ref-type="fig" rid="fig6">Figure 6</xref>, the significance between mice that received B6 CD45.1 bone marrow and mice that received <italic>Zbtb46</italic>-DTR bone marrow was calculated using one-way ANOVA and Šídák’s multiple comparisons test. For all data, *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001. Tests were run using GraphPad Prism (San Diego, CA).</p><p>The sample size for each experiment ranged from three to five mice per genotype, and two to three biological replicates (independent experiments) were performed per experiment, as indicated in figure legends. Sample size was chosen to provide the highest number of data points within the technical limitations of the tissue processing during the experiment.</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>consults for Ventus Therapeutics and Tempest Therapeutics and is a Reviewing Editor for eLife</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Funding acquisition, Resources, Supervision, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Animal studies were approved by the UC Berkeley Animal Care and Use Committee (current protocol number: AUP-2014-09-6665-2).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-72082-transrepform1-v2.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Immunofluorescence images have been deposited in Dryad and can be found at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.6078/D1ST46">https://doi.org/10.6078/D1ST46</ext-link>. All remaining data generated or analyzed during this study are included in the manuscript and supporting files; Source Data files have been provided for Figures 1-6, Figure 3-figure supplement 1, Figure 4-figure supplement 1, Figure 5-figure supplement 1, Figure 5-figure supplement 4, Figure 6-figure supplement 2.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Deets</surname><given-names>KA</given-names></name><name><surname>Vance</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Data from: Inflammasome activation leads to cDC1-independent cross-priming of CD8 T cells by epithelial cell derived antigen</data-title><source>Dryad Digital Repository</source><pub-id pub-id-type="doi">10.6078/D1ST46</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank members of the Vance and Barton Labs for discussions, Greg Barton and Ellen Robey for comments on the manuscript, Dmitri Kotov for comments on the manuscript and advice, and Roberto Chavez and Joceline Morales for technical assistance. We thank Jakob von Moltke for initial generation of the OvaFla mice. We also thank the UC Berkeley Cancer Research Laboratory Flow Cytometry facility, including Hector Nolla and Alma Valeros. <xref ref-type="fig" rid="fig4">Figure 4A</xref> was created with <ext-link ext-link-type="uri" xlink:href="https://biorender.com/">BioRender.com</ext-link>. Research reported in <xref ref-type="fig" rid="fig2">Figure 2</xref> of this publication was supported in part by the National Institutes of Health S10 program under award number 1S10RR026866-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. REV is an Investigator of the Howard Hughes Medical Institute, and research in his laboratory is funded by NIH grants AI075039, AI063302, and AI155634.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Awad</surname><given-names>F</given-names></name><name><surname>Assrawi</surname><given-names>E</given-names></name><name><surname>Louvrier</surname><given-names>C</given-names></name><name><surname>Jumeau</surname><given-names>C</given-names></name><name><surname>Georgin-Lavialle</surname><given-names>S</given-names></name><name><surname>Grateau</surname><given-names>G</given-names></name><name><surname>Amselem</surname><given-names>S</given-names></name><name><surname>Giurgea</surname><given-names>I</given-names></name><name><surname>Karabina</surname><given-names>S-A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Inflammasome biology, molecular pathology and therapeutic implications</article-title><source>Pharmacology &amp; Therapeutics</source><volume>187</volume><fpage>133</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2018.02.011</pub-id><pub-id pub-id-type="pmid">29466702</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bachem</surname><given-names>A</given-names></name><name><surname>Hartung</surname><given-names>E</given-names></name><name><surname>Güttler</surname><given-names>S</given-names></name><name><surname>Mora</surname><given-names>A</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Hegemann</surname><given-names>A</given-names></name><name><surname>Plantinga</surname><given-names>M</given-names></name><name><surname>Mazzini</surname><given-names>E</given-names></name><name><surname>Stoitzner</surname><given-names>P</given-names></name><name><surname>Gurka</surname><given-names>S</given-names></name><name><surname>Henn</surname><given-names>V</given-names></name><name><surname>Mages</surname><given-names>HW</given-names></name><name><surname>Kroczek</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Expression of XCR1 Characterizes the Batf3-Dependent Lineage of Dendritic Cells Capable of Antigen Cross-Presentation</article-title><source>Frontiers in Immunology</source><volume>3</volume><elocation-id>214</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2012.00214</pub-id><pub-id pub-id-type="pmid">22826713</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosteels</surname><given-names>C</given-names></name><name><surname>Neyt</surname><given-names>K</given-names></name><name><surname>Vanheerswynghels</surname><given-names>M</given-names></name><name><surname>van Helden</surname><given-names>MJ</given-names></name><name><surname>Sichien</surname><given-names>D</given-names></name><name><surname>Debeuf</surname><given-names>N</given-names></name><name><surname>De Prijck</surname><given-names>S</given-names></name><name><surname>Bosteels</surname><given-names>V</given-names></name><name><surname>Vandamme</surname><given-names>N</given-names></name><name><surname>Martens</surname><given-names>L</given-names></name><name><surname>Saeys</surname><given-names>Y</given-names></name><name><surname>Louagie</surname><given-names>E</given-names></name><name><surname>Lesage</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>DL</given-names></name><name><surname>Tang</surname><given-names>S-C</given-names></name><name><surname>Mayer</surname><given-names>JU</given-names></name><name><surname>Ronchese</surname><given-names>F</given-names></name><name><surname>Scott</surname><given-names>CL</given-names></name><name><surname>Hammad</surname><given-names>H</given-names></name><name><surname>Guilliams</surname><given-names>M</given-names></name><name><surname>Lambrecht</surname><given-names>BN</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Inflammatory Type 2 cDCs Acquire Features of cDC1s and Macrophages to Orchestrate Immunity to Respiratory Virus Infection</article-title><source>Immunity</source><volume>52</volume><fpage>1039</fpage><lpage>1056</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.04.005</pub-id><pub-id pub-id-type="pmid">32392463</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briseño</surname><given-names>CG</given-names></name><name><surname>Haldar</surname><given-names>M</given-names></name><name><surname>Kretzer</surname><given-names>NM</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Theisen</surname><given-names>DJ</given-names></name><name><surname>Kc</surname><given-names>W</given-names></name><name><surname>Durai</surname><given-names>V</given-names></name><name><surname>Grajales-Reyes</surname><given-names>GE</given-names></name><name><surname>Iwata</surname><given-names>A</given-names></name><name><surname>Bagadia</surname><given-names>P</given-names></name><name><surname>Murphy</surname><given-names>TL</given-names></name><name><surname>Murphy</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Distinct Transcriptional Programs Control Cross-Priming in Classical and Monocyte-Derived Dendritic Cells</article-title><source>Cell Reports</source><volume>15</volume><fpage>2462</fpage><lpage>2474</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.05.025</pub-id><pub-id pub-id-type="pmid">27264183</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broz</surname><given-names>P</given-names></name><name><surname>Newton</surname><given-names>K</given-names></name><name><surname>Lamkanfi</surname><given-names>M</given-names></name><name><surname>Mariathasan</surname><given-names>S</given-names></name><name><surname>Dixit</surname><given-names>VM</given-names></name><name><surname>Monack</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2010">2010a</year><article-title>Redundant roles for inflammasome receptors NLRP3 and NLRC4 in host defense against Salmonella</article-title><source>The Journal of Experimental Medicine</source><volume>207</volume><fpage>1745</fpage><lpage>1755</lpage><pub-id pub-id-type="doi">10.1084/jem.20100257</pub-id><pub-id pub-id-type="pmid">20603313</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broz</surname><given-names>P</given-names></name><name><surname>von Moltke</surname><given-names>J</given-names></name><name><surname>Jones</surname><given-names>JW</given-names></name><name><surname>Vance</surname><given-names>RE</given-names></name><name><surname>Monack</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2010">2010b</year><article-title>Differential requirement for Caspase-1 autoproteolysis in pathogen-induced cell death and cytokine processing</article-title><source>Cell Host &amp; Microbe</source><volume>8</volume><fpage>471</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2010.11.007</pub-id><pub-id pub-id-type="pmid">21147462</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bullen</surname><given-names>TF</given-names></name><name><surname>Forrest</surname><given-names>S</given-names></name><name><surname>Campbell</surname><given-names>F</given-names></name><name><surname>Dodson</surname><given-names>AR</given-names></name><name><surname>Hershman</surname><given-names>MJ</given-names></name><name><surname>Pritchard</surname><given-names>DM</given-names></name><name><surname>Turner</surname><given-names>JR</given-names></name><name><surname>Montrose</surname><given-names>MH</given-names></name><name><surname>Watson</surname><given-names>AJM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Characterization of epithelial cell shedding from human small intestine</article-title><source>Laboratory Investigation; a Journal of Technical Methods and Pathology</source><volume>86</volume><fpage>1052</fpage><lpage>1063</lpage><pub-id pub-id-type="doi">10.1038/labinvest.3700464</pub-id><pub-id pub-id-type="pmid">16909128</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerovic</surname><given-names>V</given-names></name><name><surname>Houston</surname><given-names>SA</given-names></name><name><surname>Westlund</surname><given-names>J</given-names></name><name><surname>Utriainen</surname><given-names>L</given-names></name><name><surname>Davison</surname><given-names>ES</given-names></name><name><surname>Scott</surname><given-names>CL</given-names></name><name><surname>Bain</surname><given-names>CC</given-names></name><name><surname>Joeris</surname><given-names>T</given-names></name><name><surname>Agace</surname><given-names>WW</given-names></name><name><surname>Kroczek</surname><given-names>RA</given-names></name><name><surname>Mowat</surname><given-names>AM</given-names></name><name><surname>Yrlid</surname><given-names>U</given-names></name><name><surname>Milling</surname><given-names>SWF</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Lymph-borne CD8α+ dendritic cells are uniquely able to cross-prime CD8+ T cells with antigen acquired from intestinal epithelial cells</article-title><source>Mucosal Immunology</source><volume>8</volume><fpage>38</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1038/mi.2014.40</pub-id><pub-id pub-id-type="pmid">24850430</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>PM</given-names></name><name><surname>Ling</surname><given-names>J</given-names></name><name><surname>Jeong</surname><given-names>YH</given-names></name><name><surname>Price</surname><given-names>DL</given-names></name><name><surname>Aja</surname><given-names>SM</given-names></name><name><surname>Wong</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Deletion of TDP-43 down-regulates Tbc1d1, a gene linked to obesity, and alters body fat metabolism</article-title><source>PNAS</source><volume>107</volume><fpage>16320</fpage><lpage>16324</lpage><pub-id pub-id-type="doi">10.1073/pnas.1002176107</pub-id><pub-id pub-id-type="pmid">20660762</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christ</surname><given-names>AD</given-names></name><name><surname>Blumberg</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>The intestinal epithelial cell: immunological aspects</article-title><source>Springer Seminars in Immunopathology</source><volume>18</volume><fpage>449</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1007/BF00824052</pub-id><pub-id pub-id-type="pmid">9144864</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chulkina</surname><given-names>M</given-names></name><name><surname>Beswick</surname><given-names>EJ</given-names></name><name><surname>Pinchuk</surname><given-names>IV</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Role of PD-L1 in Gut Mucosa Tolerance and Chronic Inflammation</article-title><source>International Journal of Molecular Sciences</source><volume>21</volume><elocation-id>23</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21239165</pub-id><pub-id pub-id-type="pmid">33271941</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cummings</surname><given-names>RJ</given-names></name><name><surname>Barbet</surname><given-names>G</given-names></name><name><surname>Bongers</surname><given-names>G</given-names></name><name><surname>Hartmann</surname><given-names>BM</given-names></name><name><surname>Gettler</surname><given-names>K</given-names></name><name><surname>Muniz</surname><given-names>L</given-names></name><name><surname>Furtado</surname><given-names>GC</given-names></name><name><surname>Cho</surname><given-names>J</given-names></name><name><surname>Lira</surname><given-names>SA</given-names></name><name><surname>Blander</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Different tissue phagocytes sample apoptotic cells to direct distinct homeostasis programs</article-title><source>Nature</source><volume>539</volume><fpage>565</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1038/nature20138</pub-id><pub-id pub-id-type="pmid">27828940</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalod</surname><given-names>M</given-names></name><name><surname>Chelbi</surname><given-names>R</given-names></name><name><surname>Malissen</surname><given-names>B</given-names></name><name><surname>Lawrence</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Dendritic cell maturation: functional specialization through signaling specificity and transcriptional programming</article-title><source>The EMBO Journal</source><volume>33</volume><fpage>1104</fpage><lpage>1116</lpage><pub-id pub-id-type="doi">10.1002/embj.201488027</pub-id><pub-id pub-id-type="pmid">24737868</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dance</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Core Concept: Cells nibble one another via the under-appreciated process of trogocytosis</article-title><source>PNAS</source><volume>116</volume><fpage>17608</fpage><lpage>17610</lpage><pub-id pub-id-type="doi">10.1073/pnas.1912252116</pub-id><pub-id pub-id-type="pmid">31481628</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Vasconcelos</surname><given-names>NM</given-names></name><name><surname>Van Opdenbosch</surname><given-names>N</given-names></name><name><surname>Van Gorp</surname><given-names>H</given-names></name><name><surname>Parthoens</surname><given-names>E</given-names></name><name><surname>Lamkanfi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Single-cell analysis of pyroptosis dynamics reveals conserved GSDMD-mediated subcellular events that precede plasma membrane rupture</article-title><source>Cell Death and Differentiation</source><volume>26</volume><fpage>146</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1038/s41418-018-0106-7</pub-id><pub-id pub-id-type="pmid">29666477</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deets</surname><given-names>KA</given-names></name><name><surname>Vance</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Inflammasomes and adaptive immune responses</article-title><source>Nature Immunology</source><volume>22</volume><fpage>412</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1038/s41590-021-00869-6</pub-id><pub-id pub-id-type="pmid">33603227</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiPeso</surname><given-names>L</given-names></name><name><surname>Ji</surname><given-names>DX</given-names></name><name><surname>Vance</surname><given-names>RE</given-names></name><name><surname>Price</surname><given-names>JV</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cell death and cell lysis are separable events during pyroptosis</article-title><source>Cell Death Discovery</source><volume>3</volume><elocation-id>17070</elocation-id><pub-id pub-id-type="doi">10.1038/cddiscovery.2017.70</pub-id><pub-id pub-id-type="pmid">29147575</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dorner</surname><given-names>BG</given-names></name><name><surname>Dorner</surname><given-names>MB</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Opitz</surname><given-names>C</given-names></name><name><surname>Mora</surname><given-names>A</given-names></name><name><surname>Güttler</surname><given-names>S</given-names></name><name><surname>Hutloff</surname><given-names>A</given-names></name><name><surname>Mages</surname><given-names>HW</given-names></name><name><surname>Ranke</surname><given-names>K</given-names></name><name><surname>Schaefer</surname><given-names>M</given-names></name><name><surname>Jack</surname><given-names>RS</given-names></name><name><surname>Henn</surname><given-names>V</given-names></name><name><surname>Kroczek</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8+ T cells</article-title><source>Immunity</source><volume>31</volume><fpage>823</fpage><lpage>833</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2009.08.027</pub-id><pub-id pub-id-type="pmid">19913446</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Downs</surname><given-names>KP</given-names></name><name><surname>Nguyen</surname><given-names>H</given-names></name><name><surname>Dorfleutner</surname><given-names>A</given-names></name><name><surname>Stehlik</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>An overview of the non-canonical inflammasome</article-title><source>Molecular Aspects of Medicine</source><volume>76</volume><elocation-id>100924</elocation-id><pub-id pub-id-type="doi">10.1016/j.mam.2020.100924</pub-id><pub-id pub-id-type="pmid">33187725</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>el Marjou</surname><given-names>F</given-names></name><name><surname>Janssen</surname><given-names>KP</given-names></name><name><surname>Chang</surname><given-names>BHJ</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Hindie</surname><given-names>V</given-names></name><name><surname>Chan</surname><given-names>L</given-names></name><name><surname>Louvard</surname><given-names>D</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name><name><surname>Metzger</surname><given-names>D</given-names></name><name><surname>Robine</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Tissue-specific and inducible Cre-mediated recombination in the gut epithelium</article-title><source>Genesis</source><volume>39</volume><fpage>186</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1002/gene.20042</pub-id><pub-id pub-id-type="pmid">15282745</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enders</surname><given-names>M</given-names></name><name><surname>Franken</surname><given-names>L</given-names></name><name><surname>Philipp</surname><given-names>M-S</given-names></name><name><surname>Kessler</surname><given-names>N</given-names></name><name><surname>Baumgart</surname><given-names>A-K</given-names></name><name><surname>Eichler</surname><given-names>M</given-names></name><name><surname>Wiertz</surname><given-names>EJH</given-names></name><name><surname>Garbi</surname><given-names>N</given-names></name><name><surname>Kurts</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Splenic Red Pulp Macrophages Cross-Prime Early Effector CTL That Provide Rapid Defense against Viral Infections</article-title><source>Journal of Immunology</source><volume>204</volume><fpage>87</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1900021</pub-id><pub-id pub-id-type="pmid">31776205</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esterházy</surname><given-names>D</given-names></name><name><surname>Canesso</surname><given-names>MCC</given-names></name><name><surname>Mesin</surname><given-names>L</given-names></name><name><surname>Muller</surname><given-names>PA</given-names></name><name><surname>de Castro</surname><given-names>TBR</given-names></name><name><surname>Lockhart</surname><given-names>A</given-names></name><name><surname>ElJalby</surname><given-names>M</given-names></name><name><surname>Faria</surname><given-names>AMC</given-names></name><name><surname>Mucida</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Compartmentalized gut lymph node drainage dictates adaptive immune responses</article-title><source>Nature</source><volume>569</volume><fpage>126</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1125-3</pub-id><pub-id pub-id-type="pmid">30988509</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evavold</surname><given-names>CL</given-names></name><name><surname>Kagan</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>How Inflammasomes Inform Adaptive Immunity</article-title><source>Journal of Molecular Biology</source><volume>430</volume><fpage>217</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2017.09.019</pub-id><pub-id pub-id-type="pmid">28987733</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evavold</surname><given-names>CL</given-names></name><name><surname>Ruan</surname><given-names>J</given-names></name><name><surname>Tan</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Kagan</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The Pore-Forming Protein Gasdermin D Regulates Interleukin-1 Secretion from Living Macrophages</article-title><source>Immunity</source><volume>48</volume><fpage>35</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.11.013</pub-id><pub-id pub-id-type="pmid">29195811</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farache</surname><given-names>J</given-names></name><name><surname>Koren</surname><given-names>I</given-names></name><name><surname>Milo</surname><given-names>I</given-names></name><name><surname>Gurevich</surname><given-names>I</given-names></name><name><surname>Kim</surname><given-names>K-W</given-names></name><name><surname>Zigmond</surname><given-names>E</given-names></name><name><surname>Furtado</surname><given-names>GC</given-names></name><name><surname>Lira</surname><given-names>SA</given-names></name><name><surname>Shakhar</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Luminal bacteria recruit CD103+ dendritic cells into the intestinal epithelium to sample bacterial antigens for presentation</article-title><source>Immunity</source><volume>38</volume><fpage>581</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.01.009</pub-id><pub-id pub-id-type="pmid">23395676</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fattinger</surname><given-names>SA</given-names></name><name><surname>Geiser</surname><given-names>P</given-names></name><name><surname>Samperio Ventayol</surname><given-names>P</given-names></name><name><surname>Di Martino</surname><given-names>ML</given-names></name><name><surname>Furter</surname><given-names>M</given-names></name><name><surname>Felmy</surname><given-names>B</given-names></name><name><surname>Bakkeren</surname><given-names>E</given-names></name><name><surname>Hausmann</surname><given-names>A</given-names></name><name><surname>Barthel-Scherrer</surname><given-names>M</given-names></name><name><surname>Gül</surname><given-names>E</given-names></name><name><surname>Hardt</surname><given-names>W-D</given-names></name><name><surname>Sellin</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Epithelium-autonomous NAIP/NLRC4 prevents TNF-driven inflammatory destruction of the gut epithelial barrier in Salmonella-infected mice</article-title><source>Mucosal Immunology</source><volume>14</volume><fpage>615</fpage><lpage>629</lpage><pub-id pub-id-type="doi">10.1038/s41385-021-00381-y</pub-id><pub-id pub-id-type="pmid">33731826</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>PA</given-names></name><name><surname>Coates</surname><given-names>PJ</given-names></name><name><surname>Ansari</surname><given-names>B</given-names></name><name><surname>Hopwood</surname><given-names>D</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Regulation of cell number in the mammalian gastrointestinal tract: the importance of apoptosis</article-title><source>Journal of Cell Science</source><volume>107 (Pt 12)</volume><fpage>3569</fpage><lpage>3577</lpage><pub-id pub-id-type="pmid">7706406</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hausmann</surname><given-names>A</given-names></name><name><surname>Böck</surname><given-names>D</given-names></name><name><surname>Geiser</surname><given-names>P</given-names></name><name><surname>Berthold</surname><given-names>DL</given-names></name><name><surname>Fattinger</surname><given-names>SA</given-names></name><name><surname>Furter</surname><given-names>M</given-names></name><name><surname>Bouman</surname><given-names>JA</given-names></name><name><surname>Barthel-Scherrer</surname><given-names>M</given-names></name><name><surname>Lang</surname><given-names>CM</given-names></name><name><surname>Bakkeren</surname><given-names>E</given-names></name><name><surname>Kolinko</surname><given-names>I</given-names></name><name><surname>Diard</surname><given-names>M</given-names></name><name><surname>Bumann</surname><given-names>D</given-names></name><name><surname>Slack</surname><given-names>E</given-names></name><name><surname>Regoes</surname><given-names>RR</given-names></name><name><surname>Pilhofer</surname><given-names>M</given-names></name><name><surname>Sellin</surname><given-names>ME</given-names></name><name><surname>Hardt</surname><given-names>W-D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Intestinal epithelial NAIP/NLRC4 restricts systemic dissemination of the adapted pathogen Salmonella Typhimurium due to site-specific bacterial PAMP expression</article-title><source>Mucosal Immunology</source><volume>13</volume><fpage>530</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1038/s41385-019-0247-0</pub-id><pub-id pub-id-type="pmid">31953493</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>W</given-names></name><name><surname>Wan</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>Z-H</given-names></name><name><surname>Zhong</surname><given-names>C-Q</given-names></name><name><surname>Han</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Gasdermin D is an executor of pyroptosis and required for interleukin-1β secretion</article-title><source>Cell Research</source><volume>25</volume><fpage>1285</fpage><lpage>1298</lpage><pub-id pub-id-type="doi">10.1038/cr.2015.139</pub-id><pub-id pub-id-type="pmid">26611636</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heilig</surname><given-names>R</given-names></name><name><surname>Dick</surname><given-names>MS</given-names></name><name><surname>Sborgi</surname><given-names>L</given-names></name><name><surname>Meunier</surname><given-names>E</given-names></name><name><surname>Hiller</surname><given-names>S</given-names></name><name><surname>Broz</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The Gasdermin-D pore acts as a conduit for IL-1β secretion in mice</article-title><source>European Journal of Immunology</source><volume>48</volume><fpage>584</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1002/eji.201747404</pub-id><pub-id pub-id-type="pmid">29274245</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heuberger</surname><given-names>C</given-names></name><name><surname>Pott</surname><given-names>J</given-names></name><name><surname>Maloy</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Why do intestinal epithelial cells express MHC class II</article-title><source>Immunology</source><volume>162</volume><fpage>357</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1111/imm.13270</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hildner</surname><given-names>K</given-names></name><name><surname>Edelson</surname><given-names>BT</given-names></name><name><surname>Purtha</surname><given-names>WE</given-names></name><name><surname>Diamond</surname><given-names>M</given-names></name><name><surname>Matsushita</surname><given-names>H</given-names></name><name><surname>Kohyama</surname><given-names>M</given-names></name><name><surname>Murphy</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity</article-title><source>Science</source><volume>322</volume><fpage>1097</fpage><lpage>1100</lpage><pub-id pub-id-type="doi">10.1126/science.1164206</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogquist</surname><given-names>KA</given-names></name><name><surname>Jameson</surname><given-names>SC</given-names></name><name><surname>Heath</surname><given-names>WR</given-names></name><name><surname>Howard</surname><given-names>JL</given-names></name><name><surname>Bevan</surname><given-names>MJ</given-names></name><name><surname>Carbone</surname><given-names>FR</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>T cell receptor antagonist peptides induce positive selection</article-title><source>Cell</source><volume>76</volume><fpage>17</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(94)90169-4</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>FP</given-names></name><name><surname>Platt</surname><given-names>N</given-names></name><name><surname>Wykes</surname><given-names>M</given-names></name><name><surname>Major</surname><given-names>JR</given-names></name><name><surname>Powell</surname><given-names>TJ</given-names></name><name><surname>Jenkins</surname><given-names>CD</given-names></name><name><surname>MacPherson</surname><given-names>GG</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes</article-title><source>The Journal of Experimental Medicine</source><volume>191</volume><fpage>435</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1084/jem.191.3.435</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ichinohe</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>HK</given-names></name><name><surname>Ogura</surname><given-names>Y</given-names></name><name><surname>Flavell</surname><given-names>R</given-names></name><name><surname>Iwasaki</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Inflammasome recognition of influenza virus is essential for adaptive immune responses</article-title><source>The Journal of Experimental Medicine</source><volume>206</volume><fpage>79</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1084/jem.20081667</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janeway</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Approaching the asymptote? Evolution and revolution in immunology</article-title><source>Cold Spring Harbor Symposia on Quantitative Biology</source><volume>54</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1101/sqb.1989.054.01.003</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joeris</surname><given-names>T</given-names></name><name><surname>Gomez-Casado</surname><given-names>C</given-names></name><name><surname>Holmkvist</surname><given-names>P</given-names></name><name><surname>Tavernier</surname><given-names>SJ</given-names></name><name><surname>Silva-Sanchez</surname><given-names>A</given-names></name><name><surname>Klotz</surname><given-names>L</given-names></name><name><surname>Agace</surname><given-names>WW</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Intestinal cDC1 drive cross-tolerance to epithelial-derived antigen via induction of FoxP3(+)CD8(+) Tregs</article-title><source>Science Immunology</source><volume>6</volume><elocation-id>60</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.abd3774</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kayagaki</surname><given-names>N</given-names></name><name><surname>Stowe</surname><given-names>IB</given-names></name><name><surname>Lee</surname><given-names>BL</given-names></name><name><surname>O’Rourke</surname><given-names>K</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name><name><surname>Warming</surname><given-names>S</given-names></name><name><surname>Dixit</surname><given-names>VM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling</article-title><source>Nature</source><volume>526</volume><fpage>666</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1038/nature15541</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kofoed</surname><given-names>EM</given-names></name><name><surname>Vance</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity</article-title><source>Nature</source><volume>477</volume><fpage>592</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1038/nature10394</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kupz</surname><given-names>A</given-names></name><name><surname>Guarda</surname><given-names>G</given-names></name><name><surname>Gebhardt</surname><given-names>T</given-names></name><name><surname>Sander</surname><given-names>LE</given-names></name><name><surname>Short</surname><given-names>KR</given-names></name><name><surname>Diavatopoulos</surname><given-names>DA</given-names></name><name><surname>Bedoui</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>NLRC4 inflammasomes in dendritic cells regulate noncognate effector function by memory CD8(+) T cells</article-title><source>Nature Immunology</source><volume>13</volume><fpage>162</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1038/ni.2195</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurachi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>CD8+ T cell exhaustion</article-title><source>Seminars in Immunopathology</source><volume>41</volume><fpage>327</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1007/s00281-019-00744-5</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurts</surname><given-names>C</given-names></name><name><surname>Heath</surname><given-names>WR</given-names></name><name><surname>Carbone</surname><given-names>FR</given-names></name><name><surname>Allison</surname><given-names>J</given-names></name><name><surname>Miller</surname><given-names>JF</given-names></name><name><surname>Kosaka</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Constitutive class I-restricted exogenous presentation of self antigens in vivo</article-title><source>The Journal of Experimental Medicine</source><volume>184</volume><fpage>923</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1084/jem.184.3.923</pub-id><pub-id pub-id-type="pmid">9064352</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurts</surname><given-names>C</given-names></name><name><surname>Kosaka</surname><given-names>H</given-names></name><name><surname>Carbone</surname><given-names>FR</given-names></name><name><surname>Miller</surname><given-names>JF</given-names></name><name><surname>Heath</surname><given-names>WR</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells</article-title><source>The Journal of Experimental Medicine</source><volume>186</volume><fpage>239</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1084/jem.186.2.239</pub-id><pub-id pub-id-type="pmid">9221753</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Mbow</surname><given-names>ML</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Griswold</surname><given-names>DE</given-names></name><name><surname>Schantz</surname><given-names>A</given-names></name><name><surname>Shealy</surname><given-names>DJ</given-names></name><name><surname>Goletz</surname><given-names>TJ</given-names></name><name><surname>Wan</surname><given-names>J</given-names></name><name><surname>Peritt</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Induction of dendritic cell maturation by IL-18</article-title><source>Cellular Immunology</source><volume>227</volume><fpage>103</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1016/j.cellimm.2004.02.002</pub-id><pub-id pub-id-type="pmid">15135292</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Lefrançois</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Intestinal epithelial antigen induces mucosal CD8 T cell tolerance, activation, and inflammatory response</article-title><source>Journal of Immunology</source><volume>173</volume><fpage>4324</fpage><lpage>4330</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.173.7.4324</pub-id><pub-id pub-id-type="pmid">15383561</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Evanoff</surname><given-names>DP</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Urinary bladder epithelium antigen induces CD8+ T cell tolerance, activation, and autoimmune response</article-title><source>Journal of Immunology</source><volume>178</volume><fpage>539</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.178.1.539</pub-id><pub-id pub-id-type="pmid">17182594</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lukowski</surname><given-names>SW</given-names></name><name><surname>Rødahl</surname><given-names>I</given-names></name><name><surname>Kelly</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Gotley</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Millard</surname><given-names>S</given-names></name><name><surname>Andersen</surname><given-names>SB</given-names></name><name><surname>Christ</surname><given-names>AN</given-names></name><name><surname>Belz</surname><given-names>G</given-names></name><name><surname>Frazer</surname><given-names>IH</given-names></name><name><surname>Chandra</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Absence of Batf3 reveals a new dimension of cell state heterogeneity within conventional dendritic cells</article-title><source>IScience</source><volume>24</volume><elocation-id>102402</elocation-id><pub-id pub-id-type="doi">10.1016/j.isci.2021.102402</pub-id><pub-id pub-id-type="pmid">33997687</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Man</surname><given-names>SM</given-names></name><name><surname>Tourlomousis</surname><given-names>P</given-names></name><name><surname>Hopkins</surname><given-names>L</given-names></name><name><surname>Monie</surname><given-names>TP</given-names></name><name><surname>Fitzgerald</surname><given-names>KA</given-names></name><name><surname>Bryant</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Salmonella infection induces recruitment of Caspase-8 to the inflammasome to modulate IL-1β production</article-title><source>Journal of Immunology</source><volume>191</volume><fpage>5239</fpage><lpage>5246</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1301581</pub-id><pub-id pub-id-type="pmid">24123685</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mariathasan</surname><given-names>S</given-names></name><name><surname>Newton</surname><given-names>K</given-names></name><name><surname>Monack</surname><given-names>DM</given-names></name><name><surname>Vucic</surname><given-names>D</given-names></name><name><surname>French</surname><given-names>DM</given-names></name><name><surname>Lee</surname><given-names>WP</given-names></name><name><surname>Roose-Girma</surname><given-names>M</given-names></name><name><surname>Erickson</surname><given-names>S</given-names></name><name><surname>Dixit</surname><given-names>VM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf</article-title><source>Nature</source><volume>430</volume><fpage>213</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1038/nature02664</pub-id><pub-id pub-id-type="pmid">15190255</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marshman</surname><given-names>E</given-names></name><name><surname>Ottewell</surname><given-names>PD</given-names></name><name><surname>Potten</surname><given-names>CS</given-names></name><name><surname>Watson</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Caspase activation during spontaneous and radiation-induced apoptosis in the murine intestine</article-title><source>The Journal of Pathology</source><volume>195</volume><fpage>285</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1002/path.967</pub-id><pub-id pub-id-type="pmid">11673824</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDaniel</surname><given-names>MM</given-names></name><name><surname>Kottyan</surname><given-names>LC</given-names></name><name><surname>Singh</surname><given-names>H</given-names></name><name><surname>Pasare</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Suppression of Inflammasome Activation by IRF8 and IRF4 in cDCs Is Critical for T Cell Priming</article-title><source>Cell Reports</source><volume>31</volume><elocation-id>107604</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.107604</pub-id><pub-id pub-id-type="pmid">32375053</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDaniel</surname><given-names>MM</given-names></name><name><surname>Meibers</surname><given-names>HE</given-names></name><name><surname>Pasare</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Innate control of adaptive immunity and adaptive instruction of innate immunity: bi-directional flow of information</article-title><source>Current Opinion in Immunology</source><volume>73</volume><fpage>25</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2021.07.013</pub-id><pub-id pub-id-type="pmid">34425435</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>McDougal</surname><given-names>CE</given-names></name><name><surname>Morrow</surname><given-names>ZT</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Carter</surname><given-names>D</given-names></name><name><surname>Stevenson</surname><given-names>DM</given-names></name><name><surname>Amador-Noguez</surname><given-names>D</given-names></name><name><surname>Sauer</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Prostaglandin E2 Induction by Cytosolic Listeria Monocytogenes in Phagocytes Is Necessary for Optimal T-Cell Priming</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2021.03.23.436585</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meredith</surname><given-names>MM</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Darrasse-Jeze</surname><given-names>G</given-names></name><name><surname>Kamphorst</surname><given-names>AO</given-names></name><name><surname>Schreiber</surname><given-names>HA</given-names></name><name><surname>Guermonprez</surname><given-names>P</given-names></name><name><surname>Idoyaga</surname><given-names>J</given-names></name><name><surname>Cheong</surname><given-names>C</given-names></name><name><surname>Yao</surname><given-names>K-H</given-names></name><name><surname>Niec</surname><given-names>RE</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Expression of the zinc finger transcription factor zDC (Zbtb46, Btbd4) defines the classical dendritic cell lineage</article-title><source>The Journal of Experimental Medicine</source><volume>209</volume><fpage>1153</fpage><lpage>1165</lpage><pub-id pub-id-type="doi">10.1084/jem.20112675</pub-id><pub-id pub-id-type="pmid">22615130</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>PS</given-names></name><name><surname>Roncaioli</surname><given-names>JL</given-names></name><name><surname>Turcotte</surname><given-names>EA</given-names></name><name><surname>Goers</surname><given-names>L</given-names></name><name><surname>Chavez</surname><given-names>RA</given-names></name><name><surname>Lee</surname><given-names>AY</given-names></name><name><surname>Lesser</surname><given-names>CF</given-names></name><name><surname>Rauch</surname><given-names>I</given-names></name><name><surname>Vance</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>NAIP-NLRC4-deficient mice are susceptible to shigellosis</article-title><source>eLife</source><volume>9</volume><elocation-id>e59022</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.59022</pub-id><pub-id pub-id-type="pmid">33074100</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakazawa</surname><given-names>A</given-names></name><name><surname>Dotan</surname><given-names>I</given-names></name><name><surname>Brimnes</surname><given-names>J</given-names></name><name><surname>Allez</surname><given-names>M</given-names></name><name><surname>Shao</surname><given-names>L</given-names></name><name><surname>Tsushima</surname><given-names>F</given-names></name><name><surname>Azuma</surname><given-names>M</given-names></name><name><surname>Mayer</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells</article-title><source>Gastroenterology</source><volume>126</volume><fpage>1347</fpage><lpage>1357</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2004.02.004</pub-id><pub-id pub-id-type="pmid">15131796</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2017">2017a</year><source>Systemic Effects Downstream of NAIP/NLRC4 Inflammasome Activation in Vivo. PhD Dissertation, University of California, Berkeley</source><publisher-name>Berkeley University of California</publisher-name></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>RD</given-names></name><name><surname>von Moltke</surname><given-names>J</given-names></name><name><surname>Vance</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2017">2017b</year><article-title>NAIP/NLRC4 inflammasome activation in MRP8+ cells is sufficient to cause systemic inflammatory disease</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>2209</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-02266-w</pub-id><pub-id pub-id-type="pmid">29263322</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikolić-Zugić</surname><given-names>J</given-names></name><name><surname>Bevan</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Role of self-peptides in positively selecting the T-cell repertoire</article-title><source>Nature</source><volume>344</volume><fpage>65</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1038/344065a0</pub-id><pub-id pub-id-type="pmid">2304556</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nordlander</surname><given-names>S</given-names></name><name><surname>Pott</surname><given-names>J</given-names></name><name><surname>Maloy</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>NLRC4 expression in intestinal epithelial cells mediates protection against an enteric pathogen</article-title><source>Mucosal Immunology</source><volume>7</volume><fpage>775</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1038/mi.2013.95</pub-id><pub-id pub-id-type="pmid">24280936</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oyesola</surname><given-names>OO</given-names></name><name><surname>Shanahan</surname><given-names>MT</given-names></name><name><surname>Kanke</surname><given-names>M</given-names></name><name><surname>Mooney</surname><given-names>BM</given-names></name><name><surname>Webb</surname><given-names>LM</given-names></name><name><surname>Smita</surname><given-names>S</given-names></name><name><surname>Matheson</surname><given-names>MK</given-names></name><name><surname>Campioli</surname><given-names>P</given-names></name><name><surname>Pham</surname><given-names>D</given-names></name><name><surname>Früh</surname><given-names>SP</given-names></name><name><surname>McGinty</surname><given-names>JW</given-names></name><name><surname>Churchill</surname><given-names>MJ</given-names></name><name><surname>Cahoon</surname><given-names>JL</given-names></name><name><surname>Sundaravaradan</surname><given-names>P</given-names></name><name><surname>Flitter</surname><given-names>BA</given-names></name><name><surname>Mouli</surname><given-names>K</given-names></name><name><surname>Nadjsombati</surname><given-names>MS</given-names></name><name><surname>Kamynina</surname><given-names>E</given-names></name><name><surname>Peng</surname><given-names>SA</given-names></name><name><surname>Cubitt</surname><given-names>RL</given-names></name><name><surname>Gronert</surname><given-names>K</given-names></name><name><surname>Lord</surname><given-names>JD</given-names></name><name><surname>Rauch</surname><given-names>I</given-names></name><name><surname>von Moltke</surname><given-names>J</given-names></name><name><surname>Sethupathy</surname><given-names>P</given-names></name><name><surname>Tait Wojno</surname><given-names>ED</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>PGD2 and CRTH2 counteract Type 2 cytokine-elicited intestinal epithelial responses during helminth infection</article-title><source>The Journal of Experimental Medicine</source><volume>218</volume><elocation-id>e20202178</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20202178</pub-id><pub-id pub-id-type="pmid">34283207</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Donnell</surname><given-names>H</given-names></name><name><surname>Pham</surname><given-names>OH</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Atif</surname><given-names>SM</given-names></name><name><surname>Lee</surname><given-names>S-J</given-names></name><name><surname>Ravesloot</surname><given-names>MM</given-names></name><name><surname>Stolfi</surname><given-names>JL</given-names></name><name><surname>Nuccio</surname><given-names>S-P</given-names></name><name><surname>Broz</surname><given-names>P</given-names></name><name><surname>Monack</surname><given-names>DM</given-names></name><name><surname>Baumler</surname><given-names>AJ</given-names></name><name><surname>McSorley</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Toll-like receptor and inflammasome signals converge to amplify the innate bactericidal capacity of T helper 1 cells</article-title><source>Immunity</source><volume>40</volume><fpage>213</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.12.013</pub-id><pub-id pub-id-type="pmid">24508233</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palazon-Riquelme</surname><given-names>P</given-names></name><name><surname>Lopez-Castejon</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The inflammasomes, immune guardians at defence barriers</article-title><source>Immunology</source><volume>155</volume><fpage>320</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1111/imm.12989</pub-id><pub-id pub-id-type="pmid">30098204</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>IK</given-names></name><name><surname>Ichinohe</surname><given-names>T</given-names></name><name><surname>Iwasaki</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>IL-1R signaling in dendritic cells replaces pattern-recognition receptors in promoting CD8+ T cell responses to influenza A virus</article-title><source>Nature Immunology</source><volume>14</volume><fpage>246</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1038/ni.2514</pub-id><pub-id pub-id-type="pmid">23314004</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pham</surname><given-names>OH</given-names></name><name><surname>O’Donnell</surname><given-names>H</given-names></name><name><surname>Al-Shamkhani</surname><given-names>A</given-names></name><name><surname>Kerrinnes</surname><given-names>T</given-names></name><name><surname>Tsolis</surname><given-names>RM</given-names></name><name><surname>McSorley</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>T cell expression of IL-18R and DR3 is essential for non-cognate stimulation of Th1 cells and optimal clearance of intracellular bacteria</article-title><source>PLOS Pathogens</source><volume>13</volume><elocation-id>e1006566</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006566</pub-id><pub-id pub-id-type="pmid">28817719</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rauch</surname><given-names>I</given-names></name><name><surname>Tenthorey</surname><given-names>JL</given-names></name><name><surname>Nichols</surname><given-names>RD</given-names></name><name><surname>Al Moussawi</surname><given-names>K</given-names></name><name><surname>Kang</surname><given-names>JJ</given-names></name><name><surname>Kang</surname><given-names>C</given-names></name><name><surname>Kazmierczak</surname><given-names>BI</given-names></name><name><surname>Vance</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>NAIP proteins are required for cytosolic detection of specific bacterial ligands in vivo</article-title><source>The Journal of Experimental Medicine</source><volume>213</volume><fpage>657</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1084/jem.20151809</pub-id><pub-id pub-id-type="pmid">27045008</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rauch</surname><given-names>I</given-names></name><name><surname>Deets</surname><given-names>KA</given-names></name><name><surname>Ji</surname><given-names>DX</given-names></name><name><surname>von Moltke</surname><given-names>J</given-names></name><name><surname>Tenthorey</surname><given-names>JL</given-names></name><name><surname>Lee</surname><given-names>AY</given-names></name><name><surname>Philip</surname><given-names>NH</given-names></name><name><surname>Ayres</surname><given-names>JS</given-names></name><name><surname>Brodsky</surname><given-names>IE</given-names></name><name><surname>Gronert</surname><given-names>K</given-names></name><name><surname>Vance</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>NAIP-NLRC4 Inflammasomes Coordinate Intestinal Epithelial Cell Expulsion with Eicosanoid and IL-18 Release via Activation of Caspase-1 and -8</article-title><source>Immunity</source><volume>46</volume><fpage>649</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.03.016</pub-id><pub-id pub-id-type="pmid">28410991</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satpathy</surname><given-names>AT</given-names></name><name><surname>KC</surname><given-names>W</given-names></name><name><surname>Albring</surname><given-names>JC</given-names></name><name><surname>Edelson</surname><given-names>BT</given-names></name><name><surname>Kretzer</surname><given-names>NM</given-names></name><name><surname>Bhattacharya</surname><given-names>D</given-names></name><name><surname>Murphy</surname><given-names>TL</given-names></name><name><surname>Murphy</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Zbtb46 expression distinguishes classical dendritic cells and their committed progenitors from other immune lineages</article-title><source>The Journal of Experimental Medicine</source><volume>209</volume><fpage>1135</fpage><lpage>1152</lpage><pub-id pub-id-type="doi">10.1084/jem.20120030</pub-id><pub-id pub-id-type="pmid">22615127</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauer</surname><given-names>JD</given-names></name><name><surname>Pereyre</surname><given-names>S</given-names></name><name><surname>Archer</surname><given-names>KA</given-names></name><name><surname>Burke</surname><given-names>TP</given-names></name><name><surname>Hanson</surname><given-names>B</given-names></name><name><surname>Lauer</surname><given-names>P</given-names></name><name><surname>Portnoy</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Listeria monocytogenes engineered to activate the Nlrc4 inflammasome are severely attenuated and are poor inducers of protective immunity</article-title><source>PNAS</source><volume>108</volume><fpage>12419</fpage><lpage>12424</lpage><pub-id pub-id-type="doi">10.1073/pnas.1019041108</pub-id><pub-id pub-id-type="pmid">21746921</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulze</surname><given-names>DH</given-names></name><name><surname>Pease</surname><given-names>LR</given-names></name><name><surname>Geier</surname><given-names>SS</given-names></name><name><surname>Reyes</surname><given-names>AA</given-names></name><name><surname>Sarmiento</surname><given-names>LA</given-names></name><name><surname>Wallace</surname><given-names>RB</given-names></name><name><surname>Nathenson</surname><given-names>SG</given-names></name></person-group><year iso-8601-date="1983">1983</year><article-title>Comparison of the cloned H-2Kbm1 variant gene with the H-2Kb gene shows a cluster of seven nucleotide differences</article-title><source>PNAS</source><volume>80</volume><fpage>2007</fpage><lpage>2011</lpage><pub-id pub-id-type="doi">10.1073/pnas.80.7.2007</pub-id><pub-id pub-id-type="pmid">6300887</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sellin</surname><given-names>ME</given-names></name><name><surname>Müller</surname><given-names>AA</given-names></name><name><surname>Felmy</surname><given-names>B</given-names></name><name><surname>Dolowschiak</surname><given-names>T</given-names></name><name><surname>Diard</surname><given-names>M</given-names></name><name><surname>Tardivel</surname><given-names>A</given-names></name><name><surname>Maslowski</surname><given-names>KM</given-names></name><name><surname>Hardt</surname><given-names>W-D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Epithelium-intrinsic NAIP/NLRC4 inflammasome drives infected enterocyte expulsion to restrict Salmonella replication in the intestinal mucosa</article-title><source>Cell Host &amp; Microbe</source><volume>16</volume><fpage>237</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2014.07.001</pub-id><pub-id pub-id-type="pmid">25121751</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selvaggi</surname><given-names>G</given-names></name><name><surname>Ricordi</surname><given-names>C</given-names></name><name><surname>Podack</surname><given-names>ER</given-names></name><name><surname>Inverardi</surname><given-names>L</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>The role of the perforin and Fas pathways of cytotoxicity in skin graft rejection</article-title><source>Transplantation</source><volume>62</volume><fpage>1912</fpage><lpage>1915</lpage><pub-id pub-id-type="doi">10.1097/00007890-199612270-00040</pub-id><pub-id pub-id-type="pmid">8990386</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Zhuang</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Shao</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death</article-title><source>Nature</source><volume>526</volume><fpage>660</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1038/nature15514</pub-id><pub-id pub-id-type="pmid">26375003</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shibahara</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>N</given-names></name><name><surname>Waguri</surname><given-names>S</given-names></name><name><surname>Iwanaga</surname><given-names>T</given-names></name><name><surname>Nakahara</surname><given-names>A</given-names></name><name><surname>Fukutomi</surname><given-names>H</given-names></name><name><surname>Uchiyama</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>The fate of effete epithelial cells at the villus tips of the human small intestine</article-title><source>Archives of Histology and Cytology</source><volume>58</volume><fpage>205</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1679/aohc.58.205</pub-id><pub-id pub-id-type="pmid">7576872</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svensson</surname><given-names>M</given-names></name><name><surname>Marsal</surname><given-names>J</given-names></name><name><surname>Ericsson</surname><given-names>A</given-names></name><name><surname>Carramolino</surname><given-names>L</given-names></name><name><surname>Brodén</surname><given-names>T</given-names></name><name><surname>Márquez</surname><given-names>G</given-names></name><name><surname>Agace</surname><given-names>WW</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>CCL25 mediates the localization of recently activated CD8alphabeta(+) lymphocytes to the small-intestinal mucosa</article-title><source>The Journal of Clinical Investigation</source><volume>110</volume><fpage>1113</fpage><lpage>1121</lpage><pub-id pub-id-type="doi">10.1172/JCI15988</pub-id><pub-id pub-id-type="pmid">12393847</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theisen</surname><given-names>E</given-names></name><name><surname>Sauer</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Listeria monocytogenes-Induced Cell Death Inhibits the Generation of Cell-Mediated Immunity</article-title><source>Infection and Immunity</source><volume>85</volume><elocation-id>e00733</elocation-id><pub-id pub-id-type="doi">10.1128/IAI.00733-16</pub-id><pub-id pub-id-type="pmid">27821585</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tourlomousis</surname><given-names>P</given-names></name><name><surname>Wright</surname><given-names>JA</given-names></name><name><surname>Bittante</surname><given-names>AS</given-names></name><name><surname>Hopkins</surname><given-names>LJ</given-names></name><name><surname>Webster</surname><given-names>SJ</given-names></name><name><surname>Bryant</surname><given-names>OJ</given-names></name><name><surname>Mastroeni</surname><given-names>P</given-names></name><name><surname>Maskell</surname><given-names>DJ</given-names></name><name><surname>Bryant</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Modifying bacterial flagellin to evade Nod-like Receptor CARD 4 recognition enhances protective immunity against Salmonella</article-title><source>Nature Microbiology</source><volume>5</volume><fpage>1588</fpage><lpage>1597</lpage><pub-id pub-id-type="doi">10.1038/s41564-020-00801-y</pub-id><pub-id pub-id-type="pmid">33106673</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trunk</surname><given-names>G</given-names></name><name><surname>Oxenius</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Innate instruction of CD4+ T cell immunity in respiratory bacterial infection</article-title><source>Journal of Immunology</source><volume>189</volume><fpage>616</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1200924</pub-id><pub-id pub-id-type="pmid">22723524</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vezys</surname><given-names>V</given-names></name><name><surname>Olson</surname><given-names>S</given-names></name><name><surname>Lefrançois</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Expression of intestine-specific antigen reveals novel pathways of CD8 T cell tolerance induction</article-title><source>Immunity</source><volume>12</volume><fpage>505</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1016/s1074-7613(00)80202-2</pub-id><pub-id pub-id-type="pmid">10843383</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Moltke</surname><given-names>J</given-names></name><name><surname>Trinidad</surname><given-names>NJ</given-names></name><name><surname>Moayeri</surname><given-names>M</given-names></name><name><surname>Kintzer</surname><given-names>AF</given-names></name><name><surname>Wang</surname><given-names>SB</given-names></name><name><surname>van Rooijen</surname><given-names>N</given-names></name><name><surname>Brown</surname><given-names>CR</given-names></name><name><surname>Krantz</surname><given-names>BA</given-names></name><name><surname>Leppla</surname><given-names>SH</given-names></name><name><surname>Gronert</surname><given-names>K</given-names></name><name><surname>Vance</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Rapid induction of inflammatory lipid mediators by the inflammasome in vivo</article-title><source>Nature</source><volume>490</volume><fpage>107</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1038/nature11351</pub-id><pub-id pub-id-type="pmid">22902502</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>AJM</given-names></name><name><surname>Chu</surname><given-names>S</given-names></name><name><surname>Sieck</surname><given-names>L</given-names></name><name><surname>Gerasimenko</surname><given-names>O</given-names></name><name><surname>Bullen</surname><given-names>T</given-names></name><name><surname>Campbell</surname><given-names>F</given-names></name><name><surname>McKenna</surname><given-names>M</given-names></name><name><surname>Rose</surname><given-names>T</given-names></name><name><surname>Montrose</surname><given-names>MH</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Epithelial barrier function in vivo is sustained despite gaps in epithelial layers</article-title><source>Gastroenterology</source><volume>129</volume><fpage>902</fpage><lpage>912</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2005.06.015</pub-id><pub-id pub-id-type="pmid">16143130</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Yue</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Gong</surname><given-names>Y-N</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Shao</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus</article-title><source>Nature</source><volume>477</volume><fpage>596</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1038/nature10510</pub-id><pub-id pub-id-type="pmid">21918512</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Shao</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Genetic functions of the NAIP family of inflammasome receptors for bacterial ligands in mice</article-title><source>The Journal of Experimental Medicine</source><volume>213</volume><fpage>647</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1084/jem.20160006</pub-id><pub-id pub-id-type="pmid">27114610</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.72082.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Chyung-Ru</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Northwestern University</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>This study uses sophisticated genetic tools to demonstrate that intestinal epithelial-derived antigens can be cross-presented by dendritic cells to activate CD8<sup>+</sup> T cells via pyroptosis-dependent and -independent pathways. The study provides novel insight into how inflammasome activation regulates CD8 T cell responses. This paper will be of interest to scientists that are interested in both innate and adaptive immune systems.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.72082.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Wang</surname><given-names>Chyung-Ru</given-names></name><role>Reviewing Editor</role><aff><institution>Northwestern University</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Wang</surname><given-names>Chyung-Ru</given-names></name><role>Reviewer</role><aff><institution>Northwestern University</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Pyroptosis-dependent and -independent cross-priming of CD8<sup>+</sup> T cells by intestinal epithelial cell-derived antigen&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Chyung-Ru Wang as Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Tadatsugu Taniguchi as the Senior Editor.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1. If would be of interest to see the effect of Asc, Gsdmd, Nlrc4-deficieny on CD4<sup>+</sup> T cell responses in the same genetic model systems (e.g. co-transfer of OVA-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells into the same recipient).</p><p>2. The authors should comment on whether endogenous OVA-specific CD8<sup>+</sup> T cell responses can be detected in these models (e.g. using tetramers or ELISPOT assays).</p><p>3. The differential expression of OVA, assessed by the GFP reporter in Figure 2, is concerning. The authors have a 2-variable system here, with mice contain different amounts of antigen and different pyroptosis-inducing potential. The authors acknowledge this point on line 216, but never do additional work to accurately quantify GFP expression across the genotypes of mice they are focused on. Additional quantification of transgene expression is critical, as the phenotypes described later in the study are modest.</p><p>4. Monitoring T cell response at day 5 post-treatment does not allow the authors to assess CD8 T cell differentiation into memory cells or functions in the context of infectious challenges with pathogens that express the OVA transgene. A suitable revision would include such analysis, where the authors examine later time points for T cell functions (20-40 days, for example) and the authors challenge these mice with pathogens (<italic>Listeria</italic>-OVA, for example), to assess functional CTL responses in a relevant setting.</p><p>5. While the OVA Fla+Villin ER-Cre model is elegant, it would have been better if the authors had also created a model to directly compare the steady state cross-presentation to CD8 T cells. The NLRC4 KO data suggest that there is steady state cross presentation happening in the absence of NLRC4 activation and there is no increase in cross-presentation because of NLRC4 activation and subsequent pyroptosis. Is it possible that the quality of primed CD8 T cells is different in the presence and absence of NLRC4. While the author examined IFNγ TNF production, granzyme B, Perforin expression or pathogen clearance experiments (<italic>Listeria</italic> OVA for example) would have tested the quality of primed CD8 T cells.</p><p>6. OT-I cross priming being independent of NLRC4 but partially dependent on gasdermin D is very interesting. Did the authors examine the MHC Class I-SIINFEKL complexes on DCs in the mesenteric lymph nodes by using either a clonotypic antibody (clone 25-D1.16) or in vitro priming of OT-I T cells by isolating DCs from mLNs. Similarly, was the activation status of cDC1s different between WT, Gasdermin DKO and NLRC4 KO mice after tamoxifen administration?</p><p>7. The study does point out that there is a Batf3 independent pathway of antigen cross -presentation to T cells that might be occurring upon activation of NLRC4 inflammasome however, the study overall might benefit from a better explanation of what other pathways or other populations of DCs might be facilitating the antigen presentation in this case. The authors do mention the recent study by Bosteel et al., briefly in the discussion but characterization of the inflammatory cDC2 population in the Nlrc4-/- might provide a better insight into the mechanism of antigen presentation.</p><p>8. While the study sets out to investigate the role of inflammasome activation and pyroptosis in CD8 T cell cross priming, based on the results, a more appropriate title would be&quot; Inflammasome activation leads to cDC1 independent cross-priming of CD8 T cells by epithelial cell derived antigen&quot;.<italic>Reviewer #1:</italic></p><p>In this study, the authors used Ova Fla Villin-Cre-ERT2 mouse model on various genetic backgrounds to demonstrate that IEC-derived antigens can be cross-presented by DC to activate CD8<sup>+</sup> T cells via pyroptosis-dependent and -independent pathways. They also showed Batf3+ dendritic cells are uniquely required for the pyroptosis-independent antigen cross-presentation pathway. Overall, the experimental designs are sound and the conclusions are largely supported by the presented data.</p><p>Major strengths</p><p>– The experiments are well executed, and the results support their conclusions.</p><p>– The findings provide novel insight into how inflammasome activation affects CD8<sup>+</sup> T cell responses.</p><p>– The design of genetic model systems used in this study is very logical.</p><p>– The data is clearly presented and well discussed.</p><p>Weaknesses:</p><p>– It is not clear whether the findings from OT-1 TCR Tg model can be extrapolated to polyclonal CD8<sup>+</sup> T cells.</p><p>– This study would be more comprehensive if the authors could also investigate CD4<sup>+</sup> T cell responses in the same genetic model systems.</p><p>– The authors should comment on some differential effects observed in the spleen and mesenteric lymph nodes.</p><p><italic>Reviewer #2:</italic></p><p>This study was focused on understanding the link between inflammasomes in intestinal epithelial cells and signals that stimulate adaptive immunity.</p><p><italic>Reviewer #3:</italic></p><p>This manuscript by Deets, K and co-authors describes the use of intricate in vivo genetic tools to understand the influence of NAIP-NLRC4 inflammasome activation and pyroptosis in IECs and subsequent activation of the adaptive immune system via cross-priming of CD8 T cells. With specific focus on the NAIP-NLRC4 inflammasome activation in IECs the authors use genetic tools leading to IEC specific expression of Ova-Fla that provides a cell specific expression of an antigen and an inflammasome activator to look at the subsequent effects on CD8 T cell priming in WT vs Asc-/-, Gsdmd-/- and Nlrc4-/- background. The authors find that NLRC4 inflammasome activation in IECs in fact is not necessary for OT-I T cell priming. The most interesting part of the manuscript are experiments described in figure 5 where BATF3 expressing cDC1s are critical for cross-priming in the absence of inflammasome activation but NLRC4 inflammasome activation bypasses the need for conventional cross-priming BATF3 expressing DCs. Finally, even though cross-priming of OT-I T cells may not require NLRC4 activation, there seems to be a minor role for Gasdermin D (and thus pyroptosis) that enhances OT-I T cell priming and expansion. The work is overall elegant and uses several sophisticated genetic tools to answer the question of how and whether inflammasome activation (in the absence of engagement of other PRRs such as TLRs) is critical for activation of adaptive immunity, specifically CD8 T cell priming here.</p><p>The weaknesses of the study are:</p><p>– The physiological relevance of the findings are unclear, since the authors fail to conduct any functional experiments, vis a vis quality of primed CD8 T cells in different scenarios (GSDMD KO, NLRC4 KO) to assess pathogen clearance.</p><p>– Failure to examine the density of peptide MHC complexes or the ability of different DCs to present antigen in vitro as a proxy for peptide MHC complexes.</p><p>– Lack of any insights into which DCs are cross-priming in the WT mice when BATF3 DCs are absent.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.72082.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1. If would be of interest to see the effect of Asc, Gsdmd, Nlrc4-deficieny on CD4<sup>+</sup> T cell responses in the same genetic model systems (e.g. co-transfer of OVA-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells into the same recipient).</p></disp-quote><p>We agree that it would be very interesting to understand and compare the responses between OVA-specific CD8<sup>+</sup> and CD4<sup>+</sup> T cells. To address this question, we adoptively transferred OVA-specific CD4<sup>+</sup> T cells (OT-IIs) into WT, <italic>Gsdmd<sup>–/–</sup></italic>, and <italic>Nlrc4<sup>–/–</sup></italic> OvaFla mice and pulsed the mice with a single day of tamoxifen chow (our standard protocol). We harvested spleens and mesenteric lymph nodes five days later. We were able to recover a small population of congenically-marked OT-IIs in the mice; however, these cells were not dividing (based on CTV labeling) and remained native (CD62L<sup>+</sup> CD44<sup>–</sup>) (<xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>). We repeated this experiment and obtained the same results.</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><caption><title>Adoptively transferred OT-II T cells fail to proliferate or become CD62L<sup>–</sup>CD44<sup>+</sup> in OvaFla mice by day five post tamoxifen chow pulse.</title><p>Shown are representative flow plots demonstrating the gating strategy for identifying OT-Iis in the mesenteric lymph nodes of WT (top), <italic>Gsdmd<sup>–/–</sup></italic> (middle), or <italic>Nlrc4<sup>–/–</sup></italic> (bottom) OvaFla mice.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72082-sa2-fig1-v2.tif"/></fig><p>Unfortunately, it is difficult to determine whether the lack of an OT-II response is because NAIP–NLRC4 activation is not sufficient to activate OVA-specific CD4<sup>+</sup> T cells or because the OT-IIs are less sensitive to small amounts of MHC-presented OVA peptide than OT-Is. Figure 1 in Li M. <italic>et al.,</italic> 2001 <italic>J Immunol</italic> (PMID 11342628) shows that, when compared with OT-Is, OT-IIs require ten-fold more OVA peptide before they show robust division in vivo, so we speculate that limiting antigen levels may be the problem here.</p><disp-quote content-type="editor-comment"><p>2. The authors should comment on whether endogenous OVA-specific CD8<sup>+</sup> T cell responses can be detected in these models (e.g. using tetramers or ELISPOT assays).</p></disp-quote><p>We used two separate approaches to identify endogenous OVA-specific CD8<sup>+</sup> T cells responses in the WT, <italic>Gsdmd<sup>–/–</sup></italic>, and <italic>Nlrc4<sup>–/–</sup></italic> OvaFla mouse lines. For the first approach, we pulsed the mice with one day of tamoxifen chow and then harvested mesenteric lymph nodes seven days later. We stained each sample with a SIINFEKL-MHC Class I tetramer and used magnetic enrichment to enhance our ability to find potentially rare OVA-specific CD8<sup>+</sup> T cell populations (PMID 31034767) (<xref ref-type="fig" rid="sa2fig2">Author response image 2</xref>). We confirmed reactivity of the tetramer with mice given OT-Is as a positive control; however, we were unable to detect tetramer positive CD8<sup>+</sup> T cells in any of the experimental groups. We repeated this experiment in chimeric K<sup>bm1+</sup> OvaFla mice, and we were again unable to identify a clear tetramer-positive population among endogenous T cells.</p><fig id="sa2fig2" position="float"><label>Author response image 2.</label><caption><title>Endogenous SIINFEKL-specific CD8<sup>+</sup> T cells cannot be found using tetramer staining in OvaFla mice at seven days post tamoxifen chow pulse.</title><p>Shown are representative flow plots demonstrating the gating strategy used to identify CD8<sup>+</sup> T cells that recognize SIINFEKL presented on MHC I. Included is a positive control from a mouse given OT-I T cells and a negative control naïve B6 mouse.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72082-sa2-fig2-v2.tif"/></fig><p>For the second approach, we followed the same tamoxifen time course outlined above, but we used an IFNγ ELISpot assay to detect CD8<sup>+</sup> T cells that are responding to SIINFEKL peptide at seven days post tamoxifen chow pulse. We were again unable to detect a peptide-specific response in endogenous CD8<sup>+</sup> T cells.</p><p>The lack of an endogenous response is likely due to technical limitations of our system. As is now more clearly noted in the manuscript starting on line 245, we occasionally see some evidence for (mild) OT-I activation in OvaFla mice lacking the Cre recombinase (Figure 3—figure supplement 1D, 1E). This suggests that the OvaFla transgene might be expressed at low levels in a Cre-independent manner. Chronic expression of OvaFla as a self-antigen would likely result in the exhaustion or deletion of the endogenous SIINFEKL-specific CD8<sup>+</sup> T cells, explaining why we find it difficult to see an endogenous response. Our strategy of transferring naïve OT-I T cells from an OvaFla-negative host circumvents this problem. Essentially, though, we believe that our system is useful primarily for studying the fate and presentation of IEC-derived antigen, using acute responses of OT-I T cells as a sensitive detector of this antigen, but is not useful for studying the response or downstream effector function of endogenous cells. This limitation is also relevant to point 4 below, and we believe it is an important point that we now discuss in the manuscript (lines 253-257). While it is possible that NAIP–NLRC4 activation in IECs is not sufficient to induce an endogenous CD8<sup>+</sup> T cell response to IEC-derived antigens, we do not feel that it is appropriate to draw that conclusion from our current negative data.</p><disp-quote content-type="editor-comment"><p>3. The differential expression of OVA, assessed by the GFP reporter in Figure 2, is concerning. The authors have a 2-variable system here, with mice contain different amounts of antigen and different pyroptosis-inducing potential. The authors acknowledge this point on line 216, but never do additional work to accurately quantify GFP expression across the genotypes of mice they are focused on. Additional quantification of transgene expression is critical, as the phenotypes described later in the study are modest.</p></disp-quote><p>The reviewer raises a key issue that we tried to highlight in the initial version, though it is agreed further analysis is in order. We fully agree that the differential expression of OVA between the WT and <italic>Nlrc4</italic><sup>–/–</sup> OvaFla mice adds a second variable to our OvaFla system that is important to control for. In the revised manuscript, we now include new quantification of GFP expression in the IECs of WT, <italic>Nlrc4<sup>–/–</sup></italic> and <italic>Gsdmd<sup>–/–</sup></italic> OvaFla mice in Figure 2C. Importantly, it appears that the OvaFla-GFP transgene is expressed at indistinguishable levels in WT and <italic>Gsdmd</italic><sup>–/–</sup> intestinal epithelial cells. Because the levels are indistinguishable, we believe the comparison of OVA-specific CD8<sup>+</sup> T cell activation between these mice can be attributed to whether or not the IECs are able to undergo pyroptosis following NAIP–NLRC4 expression.</p><disp-quote content-type="editor-comment"><p>4. Monitoring T cell response at day 5 post-treatment does not allow the authors to assess CD8 T cell differentiation into memory cells or functions in the context of infectious challenges with pathogens that express the OVA transgene. A suitable revision would include such analysis, where the authors examine later time points for T cell functions (20-40 days, for example) and the authors challenge these mice with pathogens (Listeria-OVA, for example), to assess functional CTL responses in a relevant setting.</p></disp-quote><p>As discussed above in response to point 2, we agree that our manuscript focuses only on the early events of T cell activation after NAIP–NLRC4 activation and pyroptosis. We agree with the reviewer that exploring later effects is of interest, though (as discussed above) there are technical difficulties in trying to do this with our OvaFla system. Nevertheless, in an attempt to understand how NAIP–NLRC4 activation and pyroptosis might influence the recall response of these CD8<sup>+</sup> T cells, we adoptively transferred OT-Is into WT, <italic>Gsdmd<sup>–/–</sup></italic>, and <italic>Nlrc4<sup>–/–</sup></italic> OvaFla mice, pulsed these mice with one day of tamoxifen chow, and then let the animals rest for &gt;30 days. We then infected these mice with 1×10<sup>5</sup> CFU of <italic>Listeria</italic>-OVA. We monitored the mice for weight loss and harvested the spleen and liver on day 5 post-infection. Unfortunately, we were unable to recover any of our transferred OT-Is. We believe that the chronic expression of the OvaFla transgene that likely occurs even after withdrawal of tamoxifen (PMID 15282745) results in tolerization and/or deletion of the OT-I T cells. In addition, we found that the <italic>Nlrc4<sup>–/–</sup></italic> OvaFla mice had a significantly higher CFU in their spleens relative to the other mouse lines, which further complicates the interpretation of any experiment (even if we were able to figure out how to track CD8<sup>+</sup> cells long term in our system).</p><p>Nevertheless, as an alternative approach, we tried an adoptive transfer approach. In this approach we again transferred OVA-specific CD8<sup>+</sup> T cells into each of the OvaFla mouse lines and gave these mice a single day pulse of tamoxifen chow. This time, however, we adoptively transferred the OT-Is from these OvaFla mice into naïve B6 mice. These B6 mice were rested for &gt;30 days and then challenged with 1×10<sup>5</sup> CFU of <italic>Listeria</italic>-OVA. Unfortunately, we were again unable to recover OT-Is in any mice across two separate experiments.</p><p>From the above experiments, it is difficult to determine if our inability to find a memory CD8<sup>+</sup> T cell response to <italic>Listeria</italic>-OVA after OvaFla induction is due to technical difficulties or a biological reason. Because Villin-driven Cre recombinase is capable of recombining in the stem cell laden intestinal crypts, which continuously produce nascent IECs (PMID 15282745), we hypothesized that the OvaFla might become a chronic self antigenic stimulus, leading to CD8<sup>+</sup> T cell exhaustion. To test this hypothesis, we looked at PD-1 expression on our adoptively transferred OT-Is, as this is a marker of chronic antigen exposure (e.g., see Youngblood B, <italic>et al.</italic>, 2011 <italic>Immunity</italic> PMID 21943489). We collected spleens and mesenteric lymph nodes at days 11 and 14 post initial tamoxifen chow pulse and OT-I transfer (<xref ref-type="fig" rid="sa2fig3">Author response image 3</xref>). Interestingly, we found that nearly all of the remaining OT-Is in the mesenteric lymph nodes of the <italic>Nlrc4<sup>–/–</sup></italic>OvaFla mice were PD-1<sup>+</sup>, suggesting that these cells have become exhausted. We conclude that while the OvaFla system is a powerful genetic system to examine the effect of inflammasome activation on antigen presentation and early events during T cell activation, technical limitations (primarily an inability to turn off OvaFla expression) prevent us from studying memory responses using this system.</p><fig id="sa2fig3" position="float"><label>Author response image 3.</label><caption><title>OT-Is in WT, <italic>Gsdmd<sup>–/–</sup></italic>, and <italic>Nlrc4<sup>–/–</sup></italic> OvaFla mice upregulate PD-1 at 11 and 14 days after tamoxifen chow pulse.</title><p>A. Total number of OT-Is in the mesenteric lymph nodes (left) and spleens (right) of the indicated OvaFla mouse lines at 11 and 14 days after tamoxifen chow pulse. B. Percent of OT-Is in the mesenteric lymph nodes (left) and spleens (Right) of the indicated OvaFla mouse lines that are expressing PD-1 at 11 and 14 days after tamoxifen chow pulse. Data are pooled from two biological replicates, and each dot represents an individual mouse. Data shown as mean ­± SD. Significance calculated using two-way ANOVA and Tukey’s multiple comparisons test (*<italic>p</italic> &lt; 0.05, **<italic>p</italic> &lt; 0.01, ***<italic>p</italic> &lt; 0.001).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72082-sa2-fig3-v2.tif"/></fig><disp-quote content-type="editor-comment"><p>5. While the OVA Fla+Villin ER-Cre model is elegant, it would have been better if the authors had also created a model to directly compare the steady state cross-presentation to CD8 T cells. The NLRC4 KO data suggest that there is steady state cross presentation happening in the absence of NLRC4 activation and there is no increase in cross-presentation because of NLRC4 activation and subsequent pyroptosis. Is it possible that the quality of primed CD8 T cells is different in the presence and absence of NLRC4. While the author examined IFNγ TNF production, granzyme B, Perforin expression or pathogen clearance experiments (Listeria OVA for example) would have tested the quality of primed CD8 T cells.</p></disp-quote><p>We agree that the NLRC4 KO OvaFla mice do provide a system for studying steady-state (non-inflammatory) cross-presentation of IEC-derived antigens. We also agree that a pathogen challenge experiment to compare the quality of primed OVA-specific CD8<sup>+</sup> T cells in the presence and absence of NLRC4 activation would add to our understanding of the effects of inflammasome activation on cross presentation. However, per our response to Essential Revision #4, we have been unsuccessful in our attempts to measure T cell responses after challenging the OvaFla mice with <italic>Listeria</italic>–OVA. Additionally, we have been unable to achieve clear staining for granzyme B or perforin in our activated OT-I CD8<sup>+</sup> T cells. However, our results do nevertheless uncover an important distinction between the presentation of antigens in NLRC4-deficient vs NLRC4-sufficient mice. In particular, though the use of bone marrow chimeras with <italic>Batf3<sup>–/–</sup></italic> (Figure 5) and <italic>Zbtb46<sup>–/–</sup></italic> (Figure 6, new data) donors, we discovered that cross presentation of IEC antigen following NAIP–NLRC4 activation occurs via a separate population of cDCs (presumably cDC2s) relative to steady state cross presentation in the NLRC4-deficient mice (see Discussion in manuscript and in point 7 below).</p><disp-quote content-type="editor-comment"><p>6. OT-I cross priming being independent of NLRC4 but partially dependent on gasdermin D is very interesting. Did the authors examine the MHC Class I-SIINFEKL complexes on DCs in the mesenteric lymph nodes by using either a clonotypic antibody (clone 25-D1.16) or in vitro priming of OT-I T cells by isolating DCs from mLNs. Similarly, was the activation status of cDC1s different between WT, Gasdermin DKO and NLRC4 KO mice after tamoxifen administration?</p></disp-quote><p>To examine DC presentation of the SIINFEKL peptide in the OvaFla mice, we used the highly sensitive B3Z assay to quantify the amount of SIINFEKL presented on MHC Class-I (PMID: 1378619). The B3Z assay uses a T cell hybridoma cell line, where TCR recognition of the MHC Class I-SIINFEKL complex activates a lacZ reporter. WT, <italic>Gsdmd<sup>–/–</sup></italic>, and <italic>Nlrc4<sup>–/–</sup></italic> OvaFla mice were given two days of tamoxifen chow, and on the second day, we collected mesenteric lymph nodes and depleted lymphocytes from the single cell suspensions. While the assay technically worked, as indicated by a positive control in which SIINFEKL peptide was added to some of the cells from the mesenteric lymph nodes, we were unable to detect any endogenous SIINFEKL presentation in two separate experiments. Even though the B3Z assay is designed to detect rare APCs, we suspect the frequency of SIINFEKL-MHC Class I DCs is too low in our system to accurately quantify ex vivo.</p><p>As suggested by the reviewers, to examine the activation status of cDC1s across the WT, <italic>Gsdmd<sup>–/–</sup></italic>, and <italic>Nlrc4<sup>–/–</sup></italic> OvaFla mice, we performed a similar experiment, where we gave mice from each of these lines two days of tamoxifen chow. After the third day, we harvested the spleens and lymph nodes and looked for evidence of DC maturation using the upregulation of MHC II and CD86 (also known as B7-2). We did not see any difference in cDC maturation across the OvaFla mouse lines and have added these data to Figure 5—figure supplement 1 in the revised manuscript. We suspect that the low numbers of DCs that respond and are activated in this system are not detectable by flow cytometry, and therefore the CD8<sup>+</sup> T cell response remains our most sensitive reporter of antigen presentation.</p><disp-quote content-type="editor-comment"><p>7. The study does point out that there is a Batf3 independent pathway of antigen cross -presentation to T cells that might be occurring upon activation of NLRC4 inflammasome however, the study overall might benefit from a better explanation of what other pathways or other populations of DCs might be facilitating the antigen presentation in this case. The authors do mention the recent study by Bosteel et al., briefly in the discussion but characterization of the inflammatory cDC2 population in the Nlrc4-/- might provide a better insight into the mechanism of antigen presentation.</p></disp-quote><p>We agree that our manuscript would benefit from better characterization of the <italic>Batf3</italic>-independent cross-presentation pathway seen in the WT OvaFla mice. Because red pulp macrophages (PMID: 31776205) and monocyte-derived DCs (PMID: 27264183) were recently shown to cross-present antigens in a <italic>Batf3</italic>-independent manner, we wanted to determine if the <italic>Batf3-</italic>independent APC population we see is another cDC population—presumably cDC2s—or a macrophage or moDC population.</p><p>For these experiments, we generated bone marrow chimeras where the bm1<sup>+</sup> OvaFla mice were lethally irradiated and reconstituted with bone marrow from either B6 mice or <italic>Zbtb46</italic>-diptheria toxin receptor (DTR) mice (Jax strain: 019506). The transcription factor <italic>Zbtb46</italic> drives development of classical DCs (cDC1s and cDC2s) but not other myeloid cells, including macrophages and moDCs (PMID: 22615127). Eight weeks after irradiation and reconstitution, we treated all chimeric mice with DT one day prior to OT-I transfer and tamoxifen chow pulse. The mice were treated again with DT two days after the OT-I transfer, and we euthanized the mice and collected spleens and mesenteric lymph nodes at day five post transfer. In contrast to the previous experiments using bone marrow from <italic>Batf3</italic>-deficient mice, none of the OvaFla lines that received bone marrow from <italic>Zbtb46</italic>-deficient mice had robust OT-I populations in their secondary lymphoid organs. These data suggest that the <italic>Batf3</italic>-independent cross-presenting population found following NAIP–NLRC4 activation in IECs requires <italic>Zbtb46</italic> (and is thus likely due to cDC2s). We believe these results add considerably to the manuscript, and we have updated the manuscript to include these findings in the section titled “cDCs are required for cross-presentation of IEC derived antigen” (beginning on line 378) and Figure 6.</p><disp-quote content-type="editor-comment"><p>8. While the study sets out to investigate the role of inflammasome activation and pyroptosis in CD8 T cell cross priming, based on the results, a more appropriate title would be&quot; Inflammasome activation leads to cDC1 independent cross-priming of CD8 T cells by epithelial cell derived antigen&quot;.</p></disp-quote><p>This is a terrific suggestion with which we fully agree. We have changed the title of the resubmitted manuscript to reflect this very helpful suggestion.</p></body></sub-article></article>